US20070100393A1 - Treatment of movement disorders by brain stimulation - Google Patents
Treatment of movement disorders by brain stimulation Download PDFInfo
- Publication number
- US20070100393A1 US20070100393A1 US11/641,977 US64197706A US2007100393A1 US 20070100393 A1 US20070100393 A1 US 20070100393A1 US 64197706 A US64197706 A US 64197706A US 2007100393 A1 US2007100393 A1 US 2007100393A1
- Authority
- US
- United States
- Prior art keywords
- stimulation
- stimulus
- control unit
- system control
- scu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
- A61N1/0534—Electrodes for deep brain stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3507—Communication with implanted devices, e.g. external control
- A61M2205/3523—Communication with implanted devices, e.g. external control using telemetric means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3569—Range sublocal, e.g. between console and disposable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0693—Brain, cerebrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37205—Microstimulators, e.g. implantable through a cannula
Definitions
- Movement disorders are neurologic syndromes characterized by either an excess or a paucity of movement. These disorders affect approximately two million Americans, including over one million suffering from benign essential tremor, and half a million suffering from Parkinson's Disease. A substantial percentage of those afflicted with movement disorders experience a significant decrease in quality of life, suffering such problems as incapacitating tremor, limited mobility, bradykinesia (difficulty consciously initiating movement), dysarthria (difficulty with speech), and consequent social isolation. The etiology of many movement disorders, e.g., benign essential tremor, is poorly understood. For other movement disorders, e.g., Parkinson's disease, the mechanism of the disorder and brain cells affected have been identified, but even with optimal care the disease may not be reversed and may even continue to progress.
- Parkinson's disease the mechanism of the disorder and brain cells affected have been identified, but even with optimal care the disease may not be reversed and may even continue to progress.
- Parkinson's Disease is caused by a gradual loss of dopaminergic (i.e., dopamine-secreting) neurons in the substantia nigra. Consequently, levels of dopamine decrease in the striatum (i.e., the putamen and the caudate nucleus).
- dopamine has both excitatory and inhibitory effects on the striatum, the predominant effect of the loss of dopamine is decreased inhibition (by GABA) of the internal segment of the globus pallidus. This leads to increased GABA output from the internal segment of the globus pallidus, which inhibits the ventrolateral thalamus. This leads in turn to decreased inhibition of (and ultimately decreased control over) the motor cortex.
- the subthalamic nucleus appears to increase its activity in Parkinson's Disease as well, and this is believed to contribute to the symptoms of the disease.
- ET Essential Tremor
- Benign Essential Tremor is the most common movement disorder. It is a syndrome characterized by a slowly progressive postural and/or kinetic tremor, usually affecting both upper extremities.
- the prevalence of ET in the US is estimated at 0.3-5.6% of the general population.
- a 45-year study of ET in Rochester, Minnesota reported an age- and gender-adjusted prevalence of 305.6 per 100,000 and an incidence of incidence of 23.7 per 100,000.
- ET affects both sexes equally.
- the prevalence of ET increases with age. There are bimodal peaks of onset—one in late adolescence to early adulthood and a second peak in older adulthood.
- the mean age at presentation is 35-45 years.
- ET usually presents by 65 years of age and virtually always by 70 years.
- Tremor amplitude slowly increases over time.
- Tremor frequency decreases with increasing age. An 8 12 Hz tremor is seen in young adults and a 6 8 Hz tremor is seen in the elderly.
- ET is progressive, no association has been found between age of onset and severity of disability.
- Systems for treating a movement disorder include a system control unit configured to be implanted at least partially within a patient and to generate at least one stimulus in accordance with one or more stimulation parameters adjusted to treat the movement disorder.
- the systems further include a programmable memory unit in communication with the system control unit and programmed to store the one or more stimulation parameters to at least partially define the stimulus such that the stimulus is configured to treat the movement disorder.
- a means for applying the stimulus to one or more stimulation sites within the patient is operably connected to the system control unit.
- FIG. 1A depicts the dorsal surface of the brain stem according to principles described herein.
- FIGS. 1B and 1C are section views through the brain stem depicted in FIG. 1A according to principles described herein.
- FIG. 2A depicts the medial surface of the brain according to principles described herein.
- FIG. 2B is a coronal section view of the brain of FIG. 2A according to principles described herein.
- FIGS. 3A, 3B , and 3 C show some possible configurations of an implantable microstimulator of the present invention according to principles described herein.
- FIG. 4 illustrates a lateral view of the skull and components of an exemplary system control unit according to principles described herein.
- FIG. 5 illustrates internal and external components of a stimulation system according to principles described herein.
- FIG. 6 illustrates various external components of a system control unit according to principles described herein.
- FIG. 7 depicts a system of implantable devices that communicate with each other and/or with external control/programming devices according to principles described herein.
- An implanted stimulator is configured to apply at least one stimulus to a stimulation site within a patient in accordance with one or more stimulation parameters.
- the stimulus is configured to treat a movement disorder and may include electrical stimulation and/or drug stimulation.
- “treating” a movement disorder refers to any amelioration of one or more causes and/or one or more symptoms of the movement disorder.
- ET essential tremor
- Harmaline a Monoamine Oxidase (MAO) inhibitor
- MAO Monoamine Oxidase
- primates with lesions of ventromedial tegmental tract or lateral cerebellum an ET-like tremor is produced.
- inferior olivary nucleus neurons file synchronously at the tremor frequency.
- C-2-deoxyglucose PET studies demonstrate hypermetabolism in the inferior olivary nuclei of rats and cats with harmaline-induced tremor. Stimulation of the vagus nerve helped resolve tremor in rats with harmaline-induced tremor.
- [ 18 F]-fluorodeoxyglucose PET studies identified increased glucose consumption in the medulla.
- [ 15 O]-H 2 O PET studies demonstrate an increase in medullary regional cerebral blood flow (CBF) in subjects with ET, only after the administration of ethanol, and showed bilateral overactivity of cerebellar circuitry.
- CBF medullary regional cerebral blood flow
- the nucleus tractus solitarius sends fibers bilaterally to the reticular formation and hypothalamus that are important in the reflex control of cardiovascular, respiratory, and gastrointestinal functions.
- the NTS also provides input to the dorsal motor nucleus of the vagus that enables the parasympathetic fibers of the vagus nerve to control these reflex responses.
- the NTS runs the entire length of the medulla oblongata, and the NTS receives somatic sensory input from all cranial nerves, with much of its input coming from the vagus nerve.
- the NTS receives much of its input from the vagus nerve, and since electrical stimulation of the vagus nerve has been demonstrated to be effective in the treatment of an animal model of essential tremor (i.e., for harmaline-induced tremor), then electrical stimulation of the NTS may be effective in the treatment of movement disorders such as essential tremor.
- a lesion may afford some relief.
- a lesion is irreversible, and may lead to side effects such as dysarthria or cognitive disturbances. Additionally, lesions generally yield effects on only one side of the body (the contra-lateral side), and bilateral lesions are significantly more likely to produce side effects.
- Other surgical procedures such as fetal tissue transplants, are costly and unproven.
- Parkinson's disease patients demonstrate decreased neural activity in parts of the caudate and putamen, the external segment of the globus pallidus (GPe), substantia nigra, and/or parts of the thalamus.
- GPe globus pallidus
- Levy, et al., 2001 present data based on microelectrode recordings from the GPi and the STN during administration of apomorphine, a fast-acting non-selective D 1 -dopamine and D 2 -dopamine receptor agonist.
- apomorphine a fast-acting non-selective D 1 -dopamine and D 2 -dopamine receptor agonist.
- apomorphine administered doses of apomorphine sufficient to produce relief of Parkinson symptoms, but not sufficient to induce common side effects such as dyskinetic movements. Following baseline microelectrode recordings, apomorphine was administered. The spontaneous discharge of neurons encountered before, during, and after the effect of apomorphine had waned was also sampled.
- a reduction in Parkinson symptoms (e.g., limb tremor) was observed in patients when apomorphine reached therapeutic levels.
- Apomorphine significantly decreased the overall firing rates of GPi neurons, but there was no change in the overall firing rate of neurons in the STN.
- the percentage of cells with tremor-related activity i.e., tremor cells
- tremor cells was found to be significantly reduced from 19% to 6% in the STN and from 14% to 0% in the GPi following apomorphine administration.
- Apomorphine also decreased the firing rate of STN tremor cells. As the effects of apomorphine waned, the overall firing rates of GPi neurons increased.
- this GPi discharge frequency phenomenon may occur during deep brain stimulation (DBS) as well.
- DBS deep brain stimulation
- STN subthalamic nucleus
- the subthalamic nucleus (STN) is believed to demonstrate increased neurotransmitter release in Parkinson's disease, and it responds to deep brain stimulation. Thus, it may demonstrate a similar discharge frequency phenomenon as the GPi. Since the Vim nucleus of the thalamus also responds to deep brain stimulation, it may also demonstrate a similar discharge frequency phenomenon.
- chronic electrical stimulation i.e., frequencies above 100 Hz
- stimulation parameters may be adjusted to minimize side effects while maintaining efficacy; such “fine tuning” is unavailable when producing a lesion.
- DBS chronic stimulation device for DBS
- DBS has proven to be effective for treating some patients with movement disorders; however, the current procedure is highly invasive, and the initial surgery for placement of the available system requires essentially an entire day.
- These systems require the power source and stimulation electronics to be implanted far from the electrodes, generally in the chest or elsewhere in the trunk of the body. These bulky systems therefore require extensive invasive surgery for implantation, and breakage of the long leads is highly likely.
- current DBS systems for movement disorders use no feedback for regulation of stimulation.
- FIG. 1A depicts the dorsal surface of the brain stem
- FIGS. 1B and 1C are section views through the brain stem depicted in FIG. 1A
- FIG. 2A depicts the medial surface of the brain
- FIG. 2B is a coronal section view of the brain of FIG. 2A
- FIG. 1B shows the location of the nucleus tractus solitarius (NTS) 100 .
- NTS nucleus tractus solitarius
- FIG. 1C shows the locations of the substantia nigra pars reticulata 102 (as seen in the figure, the substantia nigra pars reticulata is included in the substantia nigra, as is the substantia nigra pars compacta), the ventral intermediate (Vim) thalamic nucleus 104 , the pallidosubthalamic tracts 106 , and the pallido-thalamic axons 107 (as seen in the figure, pallido-thalamic axons are found in the lenticular fasciculus and the ansa lenticularis).
- FIG. 2B shows the location of the putamen to GPe fibers 108 .
- FIGS. 1C and 2B show the locations of the internal globus pallidus (GPi) 110 , the external globus pallidus (GPe) 112 , the putamen 116 , and the subthalamic nucleus (STN) 120 .
- an SCU also referred to herein as a stimulator, may be implanted within a patient to deliver a stimulus to one or more stimulation sites within the patient to treat one or more nerve compression syndromes.
- the stimulus may include an electrical stimulation current and/or one or more drugs that are infused into the stimulation site.
- the one or more stimulation sites referred to herein, and in the appended claims may include, but are not limited to, the NTS, the ventral intermediate thalamic nucleus, the GPi, the GPe, the STN, the pallidosubthalamic tracts, the substantia nigra pars reticulate, the pallido-thalamic axons, the putamen to GPe fibers, the subthalamo-pallidal fibers, the putamen to GPi fibers, the cerebellum, and/or any other suitable location within the brain.
- the stimulus is configured to adjust the level of neural activity in one or more of these areas, and thereby treat one or more movement disorders.
- inhibitory stimulation may be applied to one or more of these areas in order to treat one or more movement disorders.
- excitatory stimulation may be applied to one or more of these areas in order to treat one or more movement disorders.
- the terms “stimulate”, “stimulation”, and “stimulating” refer to infusion of one or more drugs at the stimulation site and/or applying one or more electrical current pulses to the stimulation site.
- stimulation parameters and/or electrical current parameters are sometimes referred to herein as simply stimulation parameters, which parameters may include amplitude, volume, pulse width, infusion rate, and the like.
- stimulation pulses may be pulses of electrical energy and/or pulses of drugs infused by various means and rates of infusion, such as intermittent infusion, infusion at a constant rate, and bolus infusion.
- stimulating drugs may include medications and other pharmaceutical compounds, anesthetic agents, synthetic or natural hormones, neurotransmitters, interleukins, cytokines, lymphokines, chemokines, growth factors (e.g., glial cell line-derived neurotrophic factor (GDNF), brain cell line-derived neurotrophic factor (BDNF)), and other intracellular and intercellular chemical signals and messengers, and the like.
- GDNF glial cell line-derived neurotrophic factor
- BDNF brain cell line-derived neurotrophic factor
- Certain neurotransmifters, hormones, and other drugs are excitatory for some tissues, yet are inhibitory to other tissues. Therefore, where, herein, a drug is referred to as an “excitatory” drug, this means that the drug is acting in an excitatory manner, although it may act in an inhibitory manner in other circumstances and/or locations.
- stimulation of an area herein may include stimulation of cell bodies and axons in the area.
- Levodopa a drug referred to as “Levodopa” is effective in some patients with Parkinson's disease.
- Levodopa is typically administered with a dopa decarboxylase inhibitor in order to prevent systemic side effects.
- Patent Cooperation Treaty publication WO 00/38669(A2) which is incorporated herein by reference in its entirety, teaches administration of naloxone to the substantia nigra for the prevention of neural degeneration.
- Naloxone is an opiate antagonist.
- Since degeneration of the substantia nigra is the primary pathology of Parkinson's disease, administration of naloxone to the substantia nigra may be therapeutic.
- the SCU includes an implantable signal generator coupled to one or more electrodes and/or an implantable pump connected to a catheter(s). These systems deliver electrical stimulation and/or one or more stimulating drugs to specific areas in the brain.
- One or more electrodes are surgically implanted in the brain to provide electrical stimulation, and/or one or more catheters are implanted in the brain to infuse the stimulating drug(s).
- the SCU includes an implantable microstimulator, such as a BION® microstimulator (Advanced Bionics® Corporation, Valencia, Calif.). Exemplary microstimulators will be described in connection with FIGS. 3A-3C .
- implantable microstimulators such as a BION® microstimulator (Advanced Bionics® Corporation, Valencia, Calif.).
- Exemplary microstimulators will be described in connection with FIGS. 3A-3C .
- Various details associated with the manufacture, operation, and use of implantable microstimulators are disclosed in U.S. Pat. Nos. 5,193,539; 5,193,540; 5,312,439; 6,185,452; 6,164,284; 6,208,894; and 6,051,017. All of these listed patents are incorporated herein by reference in their respective entireties.
- an exemplary microstimulator SCU 160 may include a narrow, elongated capsule 152 containing electronic circuitry 154 connected to electrodes 172 and 172 ′, which may pass through the walls of the capsule at either end.
- electrodes 172 and/or 172 ′ may be disposed on the outer surface or case of the SCU 160 and/or arranged on a catheter or at the end of a lead, as described below.
- electrodes 172 and 172 ′ may include a stimulating electrode (to be placed close to the target) and an indifferent electrode (for completing the circuit).
- a stimulating electrode to be placed close to the target
- an indifferent electrode for completing the circuit.
- Other configurations of microstimulator SCU 160 are possible.
- implantable microstimulator SCU 160 are sufficiently small to permit placement in or adjacent to the structures to be stimulated.
- capsule 152 may have a diameter substantially equal to or less than 4-5 millimeters and a length substantially equal to or less than 25-35 mm.
- the shape of the microstimulator may be determined by the structure of the desired target, the surrounding area, and the method of implantation.
- a thin, elongated cylinder with electrodes at the ends, as shown in FIGS. 3A, 3B , and 3 C, is one possible configuration, but other shapes, such as cylinders, disks, spheres, and helical structures, are possible, as are additional electrodes, infusion outlets, leads, and/or catheters.
- Microstimulator SCU 160 when certain configurations are used, may be implanted with a surgical tool such as a tool specially designed for the purpose, or with a hypodermic needle, or the like. Alternatively, microstimulator SCU 160 may be implanted via conventional surgical methods (e.g., via a small incision), or may be placed using endoscopic or laparoscopic techniques.
- a surgical tool such as a tool specially designed for the purpose, or with a hypodermic needle, or the like.
- microstimulator SCU 160 may be implanted via conventional surgical methods (e.g., via a small incision), or may be placed using endoscopic or laparoscopic techniques.
- the microstimulator SCU 160 may be implanted with the aid of a stereotactic frame via a minimal surgical procedure (e.g., through a small burr hole) adjacent to or at the sites mentioned above.
- a minimal surgical procedure e.g., through a small burr hole
- the microstimulator SCU 160 may be sufficiently small to be able to fit through a conventional burr hole in the skull.
- Alternative implantation methods include CT scan or ultrasound image guidance.
- microstimulator SCU 160 may advantageously be composed of biocompatible materials.
- Capsule 152 may be made of, for instance, glass, ceramic, or other material that provides a hermetic package that will exclude water vapor but permit passage of electromagnetic fields used to transmit data and/or power.
- Electrodes 172 and 172 ′ may be made of a noble or refractory metal or compound, such as platinum, iridium, tantalum, titanium, titanium nitride, niobium or alloys of any of these, in order to avoid corrosion or electrolysis which could damage the surrounding tissues and the device.
- the microstimulator SCU 160 may include two leadless electrodes disposed on an outer surface or case thereof.
- either or both electrodes 172 and 172 ′ may alternatively be located at the ends of short, flexible leads.
- the use of such leads permits, among other things, electrical stimulation to be directed more locally to targeted tissue(s) a short distance from the surgical fixation of the bulk of microstimulator SCU 160 , while allowing most elements of the microstimulator to be located in a more surgically convenient site. This minimizes the distance traversed and the surgical planes crossed by the device and any lead(s).
- the SCU 160 may be implanted beneath the scalp, such as in a surgically-created shallow depression or opening in the skull 140 .
- the surgically-created shallow depression or opening may be located in the parietal bone 141 , the temporal bone 142 , and/or the frontal bone 143 .
- the SCU 160 is configured to conform to the profile of surrounding tissue(s) and/or bone(s). This may minimize pressure applied to the skin or scalp, which pressure may result in skin erosion or infection.
- one or more electrode leads 170 and/or catheters 180 attached to SCU 160 run subcutaneously, for instance, in a surgically-created shallow groove(s) in the skull, to an opening(s) in the skull, and pass through the opening(s) into or onto the brain parenchyma and surrounding tissue.
- Recessed placement of the SCU and the lead(s) and/or catheter(s) may decrease the likelihood of erosion of the overlying skin, and may minimize any cosmetic impact.
- electrode(s) 172 are carried on lead 170 having a proximal end coupled to SCU 160 .
- the lead contains insulated wires electrically connecting electrodes 172 to SCU 160 .
- SCU 160 contains electrical components 154 that produce electrical stimulation pulses that travel through the wires of lead 170 and are delivered to electrodes 172 , and thus to the tissue surrounding electrodes 172 .
- some or all of the case of the SCU may be hermetically sealed.
- the case may be made of metal (e.g. titanium) or ceramic, which materials are also, advantageously, biocompatible.
- SCU 160 may be configured to be Magnetic Resonance Imaging (MRI) compatible.
- MRI Magnetic Resonance Imaging
- the electrical stimulation may be provided as described in International Patent Application Serial Number PCT/US01/04417 (the '417 application), filed Feb. 12, 2001, and published Aug. 23, 2001 as WO 01/60450, which application is incorporated herein by reference in its entirety.
- SCU 160 may contain at least one pump 162 for storing and dispensing one or more drugs through outlet(s) 182 / 182 ′ and/or catheter(s) 180 / 180 ′ into a predetermined site(s) in the brain tissue.
- a catheter When a catheter is used, it includes at least one infusion outlet 182 , usually positioned at least at a distal end, while a proximal end of the catheter is connected to SCU 160 .
- At least one lead 170 may be coupled to SCU 160 via a suitable connector 168 .
- Additional leads 170 ′ and/or catheter(s) 180 ′ may be attached to SCU 160 as may serve a particular application.
- FIG. 5 shows (in phantom lines) a second catheter 180 ′, and a second lead 170 ′, having electrodes 172 ′ thereon, also attached to SCU 160 .
- the SCUs 160 of FIGS. 3A, 3B , and 3 C have outlets 182 , 182 ′ for infusing a stimulating drug(s) and electrodes 172 , 172 ′ for applying electrical stimulation.
- the catheters 160 and/or leads 170 are substantially cylindrical. In some alternative examples, one or more of the leads 170 may be paddle-shaped. Electrodes 172 , 172 ′ on leads 170 , 170 ′ may be arranged as an array, for instance, as two or more collinear electrodes, or even as four or more collinear electrodes, or they may not be collinear. A tip electrode may also be supplied at the distal end of one or more leads.
- SCU 160 is programmable to produce either monopolar electrical stimulation, e.g., using the SCU case as an indifferent electrode, or bipolar electrical stimulation, e.g., using one of the electrodes of the electrode array as an indifferent electrode.
- the SCU 160 may have at least four channels and drive up to sixteen or more electrodes.
- SCU 160 may additionally or alternatively include electronic circuitry 154 for receiving data and/or power from outside the body by inductive radio frequency (RF), or other electromagnetic coupling.
- electronic circuitry 154 may include an inductive coil for receiving and transmitting RF data and/or power, an integrated circuit (IC) chip for decoding and storing stimulation parameters and generating stimulation pulses (either intermittent or continuous), and additional discrete electronic components required to complete the electronic circuit functions, e.g. capacitor(s), resistor(s), coil(s), and the like.
- IC integrated circuit
- electronic circuitry 154 includes a processor and/or other components configured to generate one or more stimulation pulses that are applied to a patient 208 through electrodes 172 in accordance with one or more stimulation parameters stored in a programmable memory unit 164 .
- the processor may be configured to control stimulation parameters associated with drug stimulation.
- the processor may be configured to cause the SCU 160 to vary the rate of infusion (e.g., intermittent infusion, infusion at a constant rate, and bolus infusion).
- SCU 160 may also include a programmable memory 164 for storing one or more sets of data and/or stimulation parameters.
- memory 164 may allow electrical and/or drug stimulation to be adjusted to settings that are safe and efficacious with minimal discomfort for each individual. Specific parameters may provide therapeutic advantages for various types and severities of movement disorders. For instance, some patients may respond favorably to intermittent stimulation, while others may require continuous treatment for relief.
- electrical and drug stimulation parameters are controlled independently, e.g., continuous electrical stimulation and no drug stimulation. However, in some instances, they may advantageously be coupled, e.g., electrical stimulation may be programmed to occur only during drug infusion.
- stimulation parameters may have different effects on neural tissue. Therefore, parameters may be chosen to target specific neural populations and/or to exclude others, or to increase neural activity in specific neural populations and/or to decrease neural activity in others. For example, relatively low levels of stimulation current (e.g., anywhere between about 0.05 mA to about 5.0 mA) are likely to recruit only relatively large diameter fibers. In some examples, the stimulation may be configured to selectively increase neural activity of only the relatively large diameter fibers of NTS 100 . Relatively low amplitude electrical current pulses are likely to produce such selective excitation.
- relatively low frequency neurostimulation i.e., less than about 100-150 Hz
- relatively high frequency neurostimulation i.e., greater than about 100-150 Hz
- relatively low frequency neurostimulation typically has an excitatory effect on surrounding neural tissue, leading to increased neural activity
- relatively high frequency neurostimulation i.e., greater than about 100-150 Hz
- excitatory neurotransmitters e.g., glutamate, dopamine, norepinephrine, epinephrine, acetylcholine, serotonin
- agonists thereof e.g., glutamate receptor agonist(s), apomorphine
- agents that act to increase levels of an excitatory neurotransmitter(s) e.g., edrophonium, Mestinon
- inhibitory neurotransmitters e.g., dopamine, glycine, and gamma-aminobutyric acid, a.k.a.
- GABA GABA
- agonists thereof e.g., muscimol, apomorphine
- agents that act to increase levels of an inhibitory neurotransmitter(s) generally have an inhibitory effect.
- Dopamine acts as an excitatory neurotransmitter in some locations and circumstances, and as an inhibitory neurotransmitter in other locations and circumstances.
- antagonists of inhibitory neurotransmitters e.g., bicuculline
- agents that act to decrease levels of an inhibitory neurotransmitter(s) have been demonstrated to excite neural tissue, leading to increased neural activity.
- excitatory neurotransmitter antagonists e.g.
- prazosin, metoprolol, atropine, benztropine and agents that decrease levels of excitatory neurotransmitter(s) (e.g., acetylcholinesterase, Group II metabotropic glutamate receptor (mGluR) agonists such as DCG-IV) may inhibit neural activity.
- excitatory neurotransmitter(s) e.g., acetylcholinesterase, Group II metabotropic glutamate receptor (mGluR) agonists such as DCG-IV
- DCG-IV excitatory neurotransmitter
- the SCU 160 may also include a power source 166 .
- the power source 166 may include a self-contained power source utilizing any suitable means of generation or storage of energy (e.g., a primary battery, a replenishable or rechargeable battery such as a lithium ion battery, an electrolytic capacitor, a super- or ultra-capacitor, or the like), a rechargeable power source, and/or means receiving power from an external power source.
- the SCU 160 may be configured to receive power from an external battery charging system (EBCS) 192 , typically through an inductive link 194 .
- EBCS battery charging system
- the SCU 160 operates independently.
- the SCU 160 operates in a coordinated manner with other SCU(s), other implanted device(s), and/or other device(s) external to the patient's body.
- an SCU 160 may control or operate under the control of another implanted SCU(s), other implanted device(s), and/or other device(s) external to the patient's body.
- An SCU may communicate with other implanted SCUs, other implanted devices, and/or devices external to a patient's body via, e.g., an RF link, an ultrasonic link, a thermal link, and/or an optical link.
- an SCU may communicate with an external remote control (e.g., patient and/or physician programmer) that is configured to send commands and/or data to an SCU and that may also be capable of receiving commands and/or data from an SCU.
- an external remote control e.g., patient and/or physician programmer
- the SCU 160 may be activated, deactivated, programmed, and/or tested through a hand held programmer (HHP) 200 (which may also be referred to as a patient programmer and may be, but is not necessarily, hand held), a clinician programming system (CPS) 202 (which may also be hand held), and/or a manufacturing and diagnostic system (MDS) 204 (which may also be hand held).
- HHP 200 may be coupled to SCU 160 via an RF link 195 .
- MDS 204 may be coupled to SCU 160 via another RF link 196 .
- CPS 202 may be coupled to HHP 200 via an infra-red link 197 ; and MDS 204 may be coupled to HHP 200 via another infra-red link 198 .
- Other types of telecommunicative links, other than RF or infra-red may also be used for this purpose.
- CPS 202 may be coupled through HHP 200 to SCU 160 for programming or diagnostic purposes.
- MDS 204 may also be coupled to SCU 160 , either directly through RF link 196 , or indirectly through IR link 198 , HHP 200 , and RF link 195 .
- External components for programming and/or providing power to the SCU 160 are also illustrated in FIG. 6 .
- patient 208 is positioned on or near external appliance 220 , which appliance contains one or more inductive coils 222 or other means of communication (e.g., RF transmitter and receiver).
- External appliance 220 is connected to or is a part of external electronic circuitry appliance 230 which may receive power 232 from a conventional power source.
- External appliance 230 contains manual input means 238 , e.g., a keypad, whereby the patient 208 or a caregiver 242 may request changes in electrical and/or drug stimulation parameters produced during the normal operation of SCU 160 .
- manual input means 238 includes various electromechanical switches and/or visual display devices that provide the patient and/or caregiver with information about the status and prior programming of SCU 160 .
- the patient 208 switches SCU 160 on and off by use of controller 210 , which may be handheld.
- SCU 160 is operated by controller 210 by any of various means, including sensing the proximity of a permanent magnet located in controller 210 , sensing RF transmissions from controller 210 , or the like.
- external electronic appliance 230 is provided with an electronic interface means 246 for interacting with other computing means 248 , such as by a serial interface cable or infrared link to a personal computer or to a telephone modem or the like.
- interface means 246 may permit a clinician to monitor the status of the implant and prescribe new stimulation parameters from a remote location.
- the external appliance(s) may be embedded in a cushion, pillow, hat, or the like. Other possibilities exist, including a head band, patch, or other structure(s) that may be affixed to the patient's body or clothing. External appliances may include a package that can be, e.g., worn on the belt, may include an extension to a transmission coil affixed, e.g., with a Velcro® band or an adhesive, or may be combinations of these or other structures able to perform the functions described herein.
- a patient's response to and/or need for treatment may be sensed. For example, head acceleration, electrical activity of the brain (e.g., EEG or discharge frequency of a neural population), nerve activity (e.g., ENG), muscle activity (e.g., limb EMG), or other activity may be sensed.
- EEG electronic glycol
- nerve activity e.g., ENG
- muscle activity e.g., limb EMG
- one or more electrodes may be used for recording electrical signals from the brain. Recording of the neural activity of one or more areas being stimulated, e.g., NTS 100 or pallido-subthalamic tracts 106 , may be performed in order to determine the discharge frequency of the neural population. This sensing may occur during stimulation or during a temporary suspension of stimulation. In some examples, the amplitude of stimulation is increased if the discharge frequency is above a programmable threshold frequency, and the amplitude of stimulation is decreased if the discharge frequency is less than another programmable threshold frequency. The two programmable threshold frequencies may be the same or may be different in order to achieve hysteresis.
- one or more accelerometers may be used for sensing acceleration of the head.
- Rhythmic acceleration of the head is seen in head tremor.
- the amplitude of rhythmic head acceleration is an indicator of the amplitude of head tremor.
- the amplitude of stimulation is increased if the amplitude of rhythmic head acceleration is above a programmable threshold amplitude, and the amplitude of stimulation is decreased if the amplitude of rhythmic head acceleration is below a programmable threshold amplitude.
- the two programmable threshold amplitudes may be the same or may be different in order to achieve hysteresis. This sensing may advantageously be used for patients with significant head tremor as a component of their movement disorder, such as certain patients with benign essential tremor.
- neurotransmitter levels such as neurotransmitter levels, their associated breakdown product levels, hormone levels, or other substances, such as dopamine levels, interleukins, cytokines, lymphokines, chemokines, growth factors, electrolytes, enzymes, medication, and/or other drug levels, or levels of any other bloodborne substance(s), and/or changes in one or more of these may be sensed, using, e.g., one or more Chemically Sensitive Field-Effect Transistors (CHEMFETs) such as Enzyme-Selective Field-Effect Transistors (ENFETs) or Ion-Sensitive Field-Effect Transistors (ISFETs, as are available from Sentron CMT of Enschede, The Netherlands).
- CHEMFETs Chemically Sensitive Field-Effect Transistors
- ENFETs Enzyme-Selective Field-Effect Transistors
- ISFETs Ion-Sensitive Field-Effect Trans
- a stimulating electrode of SCU 160 may be used to sense changes in neural firing frequency of the pallido-subthalamic tracts 106 resulting from the electrical and/or drug stimulation applied to the pallido-subthalamic tracts 106 .
- adjacent or “near” means as close as reasonably possible to targeted tissue, including touching or even being positioned within the tissue, but in general, may be as far as about 150 mm from the target tissue.
- an SCU dedicated to sensory processes communicates with an SCU providing stimulation pulses.
- the implanrt circuitry 154 may, if necessary, amplify and transmit these sensed signals, which may be digital or analog.
- Other methods of determining the required electrical and/or drug stimulation include measuring impedance, acidity/alkalinity (via a pH sensor), muscle EMG, head or limb acceleration (e.g., via accelerometer), EEG, ENG, other methods mentioned herein, and others that will be evident to those of skill in the field upon review of the present disclosure.
- the sensed information may be used to control stimulation parameters in a closed-loop manner.
- a first and second “SCU” are provided.
- the second “SCU” periodically (e.g. once per minute) records firing rate of neurons in GPi 110 (or the level of a substance, e.g., dopamine or L-Dopa, or an amount of electrical activity, etc.), which it transmits to the first SCU.
- the first SCU uses the sensed information to adjust electrical and/or drug stimulation parameters according to an algorithm programmed, e.g., by a physician. For example, the amplitude and/or frequency of electrical stimulation may be increased in response to increased firing rate of neurons in GPi 110 .
- one SCU performs both the sensing and stimulating functions.
- an SCU 160 may also incorporate means of sensing symptoms or other prognostic or diagnostic indicators of movement disorders, e.g., via sensing of tremor (e.g., via accelerometer), sensing of dopamine or dopamine agonist levels (e.g., L-dopa), and/or sensing of neural electrical activity (e.g., firing rate of neurons in pallido-subthalamic tracts 106 ), it may alternatively or additionally be desirable to use a separate or specialized implantable device to record and telemeter physiological conditions/responses in order to adjust electrical stimulation and/or drug infusion parameters. This information may be transmitted to an external device, such as external appliance 220 , or may be transmitted directly to implanted SCU(s) 160 . However, in some cases, it may not be necessary or desired to include a sensing function or device, in which case stimulation parameters are determined and refined, for instance, by patient feedback, or the like.
- tremor e.g., via accelerometer
- one or more external appliances may be provided to interact with SCU 160 , and may be used to accomplish at least one or more of the following functions:
- Function 1 If necessary, transmit electrical power to the SCU 160 in order to power the SCU 160 and/or recharge the SCU 160 .
- Function 2 Transmit data to the SCU 160 in order to change the stimulation parameters used by the SCU 160 .
- Function 3 Receive data indicating the state of the SCU 160 (e.g., battery level, drug level, stimulation parameters, etc.).
- an exemplary method of treating one or more movement disorders may be carried out according to the following sequence of procedures.
- the steps listed below may be modified, reordered, and/or added to as best serves a particular application.
- a first SCU 160 is implanted so that its electrodes 172 and/or infusion outlet 182 are located in or on or near pallido-subthalamic tracts 106 . Electrodes 172 ′ and/or infusion outlets 182 ′ may additionally or alternatively be located in or on or near NTS 100 or putamen to GPi fibers.
- first SCU 160 is commanded to produce a series of excitatory electrical stimulation pulses, possibly with gradually increasing amplitude, and possibly while infusing gradually increasing amounts of an excitatory neurotransmitter, e.g., glutamate, or an inhibitory neurotransmitter antagonist, e.g., bicuculline.
- an excitatory neurotransmitter e.g., glutamate
- an inhibitory neurotransmitter antagonist e.g., bicuculline.
- any change in, e.g., tremor (sensed, e.g., via accelerometer in limb) resulting from the electrical and/or drug stimulation is sensed, for instance, by one or more electrodes 172 , 172 ′ or sensors of a second SCU 160 , preferably a microstimulator SCU 160 , implanted in or on or near a limb(s). These responses may be converted to data and telemetered out to external electronic appliance 230 .
- the stimulus threshold for obtaining a response is determined and used by a clinician 242 acting directly 238 or by other computing means 248 to transmit the desired electrical and/or drug stimulation parameters to first SCU 160 .
- the second SCU 160 uses the response data to determine the stimulation parameters and transmits the parameters to first SCU 160 .
- the second SCU 160 transmits the response data to first SCU 160 , which uses the response data directly to determine the stimulation parameters.
- patient 208 desires to invoke electrical stimulation and/or drug infusion, patient 208 employs controller 210 to set first SCU 160 in a state where it delivers a prescribed stimulation pattern from a predetermined range of allowable stimulation patterns.
- patient 208 employs controller 210 to turn off first SCU 160 and possibly also second SCU 160 .
- a treatment for movement disorders e.g., essential tremor
- a treatment for movement disorders may be carried out according to the following sequence of procedures:
- An SCU 160 is implanted so that its electrodes 172 and possibly also infusion outlet 182 are located in or on or near NTS 100 .
- First SCU 160 is commanded to produce a series of excitatory electrical stimulation pulses, possibly with gradually increasing amplitude, and possibly while infusing gradually increasing amounts of an excitatory neurotransmitter, e.g., glutamate, or an inhibitory neurotransmitter antagonist, e.g., bicuculline.
- an excitatory neurotransmitter e.g., glutamate
- an inhibitory neurotransmitter antagonist e.g., bicuculline.
- any change in movement disorder signs and symptoms e.g., change in neural firing rate in GPi 110 , resulting from the electrical and/or drug stimulation is sensed, for instance, by one or more of the electrodes 172 of SCU 160 . These responses are converted to data and telemetered out to external electronic appliance 230 .
- the stimulus threshold for obtaining a response is determined and is used by a clinician 242 acting directly 238 or by other computing means 248 to transmit the desired electrical and/or drug stimulation parameters to SCU. 160 .
- patient 208 desires to invoke electrical stimulation and/or drug infusion, patient 208 employs controller 210 to set SCU 160 in a state where it delivers a prescribed stimulation pattern from a predetermined range of allowable stimulation patterns.
- patient 208 employs controller 210 to turn off SCU 160 .
- any of the various types and severities of movement disorders it may be desirable to modify or adjust the algorithmic functions performed by the implanted and/or external components, as well as the surgical approaches, in ways that would be obvious to skilled practitioners of these arts.
- Multiple channels and/or multiple patterns of electrical and/or drug stimulation might thereby be programmed by the clinician and controlled by the patient in order to, for instance, deal with complex or multiple symptoms or conditions, such as Parkinson's disease coupled with side effects from medication, e.g., dyskinesia.
- a group of two or more SCUs 160 is controlled via closed-loop operation.
- a need for and/or response to stimulation is sensed via SCU 160 , or by an additional SCU (which may or may not be dedicated to the sensing function), or by another implanted or external device. If necessary, the sensed information is transmitted to SCU 160 . In some cases, the sensing and stimulating are performed by one SCU. In some examples, the parameters used by SCU 160 are automatically adjusted based on the sensed information. Thus, the electrical and/or drug stimulation parameters are adjusted in a closed-loop manner to provide stimulation tailored to the need for and/or response to the electrical and/or drug stimulation.
- a first SCU 160 implanted beneath the skin of the patient 208 , provides a first medication or substance; a second SCU 160 ′ provides a second medication or substance; and a third SCU 160 ′′ provides electrical stimulation via electrodes 172 and 172 ′.
- the implanted devices may operate independently or may operate in a coordinated manner with other similar implanted devices, other implanted devices, or other devices external to the patient's body, as shown by the control lines 262 , 263 and 264 in FIG. 7 . That is, the external controller 250 controls the operation of each of the implanted devices 160 , 160 ′ and 160 ′′.
- the SCU 160 may incorporate communication means for communicating with one or more external or site-specific drug delivery devices, and, further, may have the control flexibility to synchronize and control the duration of drug delivery.
- the associated drug delivery device typically provides a feedback signal that lets the control device know it has received and understood commands.
- the communication signal between the implanted SCU 160 and the drug delivery device may be encoded to prevent the accidental or inadvertent delivery of drugs by other signals.
- the electrical and/or drug stimulation decreases activity of one or more areas of the brain that exhibit chronic increased activity, relative to control subjects, in patients experiencing a movement disorder(s). These areas may include one or more of the pallido-thalamic axons 107 , putamen to GPe fibers 108 , and/or subthalamo-pallidal fibers.
- Such inhibitory stimulation is likely to be produced by relatively high-frequency electrical stimulation (e.g., greater than about 100-150 Hz), an excitatory neurotransmitter antagonist(s) (e.g.
- prazosin, metoprolol, atropine an inhibitory neurotransmitter(s) (e.g., GABA), an agonist thereof, an agent that increases the level of an inhibitory neurotransmitter, an agent that decreases the level of an excitatory neurotransmitter (e.g., DCG-IV), a local anesthetic agent (e.g., lidocaine), and/or an analgesic medication.
- This stimulation may be applied to one or more of the pallido-thalamic axons 107 , putamen to GPe fibers 108 , and subthalamo-pallidal fibers to treat movement disorder(s).
- the electrical and/or drug stimulation increases activity of one or more of those areas of the brain that exhibit chronic decreased activity, relative to control subjects, in patients experiencing a movement disorder(s), thereby treating or preventing such disorder(s) and/or the symptoms and/or pathological consequences thereof.
- These areas may include one or more of the NTS 100 , pallido-subthalamic tracts 106 , and putamen to GPi fibers.
- Such excitatory stimulation is likely to be produced by relatively low-frequency electrical stimulation (e.g., less than about 100-150 Hz), an excitatory neurotransmitter (e.g., glutamate, acetylcholine), an excitatory cortical neurotransmitter agonist (e.g., glutamate receptor agonist, L-aspartic acid, N-methyl-D-aspartic acid (NMDA), bethanechol, norepinephrine), an inhibitory neurotransmitter antagonist(s) (e.g., bicuculline), an agent that increases the level of an excitatory neurotransmitter (e.g., edrophonium), and/or an agent that decreases the level of an inhibitory neurotransmitter.
- This stimulation may be applied to one or more of the NTS 100 , pallidosubthalamic tracts 106 , and putamen to GPi fibers to treat movement disorder(s).
- the stimulation selectively increases neural activity of the relatively large diameter fibers of the nucleus tractus solitarius (NTS 100 ).
- Relatively low amplitude e.g., about 0.05 mA to about 5.0 mA
- electrical current pulses are likely to produce such selective excitation.
- one or more stimulating drugs are infused into the brain.
- a growth factor such as glial cell line-derived neurotrophic factor (GDNF) may be infused into the putamen 116 , possibly while providing electrical stimulation as described above.
- Other stimulating drugs are described previously herein and include brain cell line-derived neurotrophic factor (BDNF), naloxone, and levodopa.
- sensing means described earlier may be used to orchestrate first the activation of SCU(s) targeting an area(s) of the brain, and then, when appropriate, SCU(s) targeting another area(s) and/or by different means.
- this orchestration may be programmed, and not based on a sensed condition.
Abstract
Systems for treating a movement disorder include a system control unit configured to be implanted at least partially within a patient and to generate at least one stimulus in accordance with one or more stimulation parameters adjusted to treat the movement disorder. The systems further include a programmable memory unit in communication with the system control unit and programmed to store the one or more stimulation parameters to at least partially define the stimulus such that the stimulus is configured to treat the movement disorder. A means for applying the stimulus to one or more stimulation sites within the patient is operably connected to the system control unit.
Description
- The present application is a continuation application of U.S. application Ser. No. 10/428,744, filed May 2, 2003, which application claims the benefit of Provisional Application Ser. No. 60/383,316, filed May 24, 2002. Both applications are incorporated herein by reference in their entireties.
- Movement disorders are neurologic syndromes characterized by either an excess or a paucity of movement. These disorders affect approximately two million Americans, including over one million suffering from benign essential tremor, and half a million suffering from Parkinson's Disease. A substantial percentage of those afflicted with movement disorders experience a significant decrease in quality of life, suffering such problems as incapacitating tremor, limited mobility, bradykinesia (difficulty consciously initiating movement), dysarthria (difficulty with speech), and consequent social isolation. The etiology of many movement disorders, e.g., benign essential tremor, is poorly understood. For other movement disorders, e.g., Parkinson's disease, the mechanism of the disorder and brain cells affected have been identified, but even with optimal care the disease may not be reversed and may even continue to progress.
- Parkinson's Disease is caused by a gradual loss of dopaminergic (i.e., dopamine-secreting) neurons in the substantia nigra. Consequently, levels of dopamine decrease in the striatum (i.e., the putamen and the caudate nucleus). Although dopamine has both excitatory and inhibitory effects on the striatum, the predominant effect of the loss of dopamine is decreased inhibition (by GABA) of the internal segment of the globus pallidus. This leads to increased GABA output from the internal segment of the globus pallidus, which inhibits the ventrolateral thalamus. This leads in turn to decreased inhibition of (and ultimately decreased control over) the motor cortex. The subthalamic nucleus appears to increase its activity in Parkinson's Disease as well, and this is believed to contribute to the symptoms of the disease.
- Essential Tremor (ET), a.k.a., Benign Essential Tremor, is the most common movement disorder. It is a syndrome characterized by a slowly progressive postural and/or kinetic tremor, usually affecting both upper extremities. The prevalence of ET in the US is estimated at 0.3-5.6% of the general population. A 45-year study of ET in Rochester, Minnesota reported an age- and gender-adjusted prevalence of 305.6 per 100,000 and an incidence of incidence of 23.7 per 100,000.
- ET affects both sexes equally. The prevalence of ET increases with age. There are bimodal peaks of onset—one in late adolescence to early adulthood and a second peak in older adulthood. The mean age at presentation is 35-45 years. ET usually presents by 65 years of age and virtually always by 70 years. Tremor amplitude slowly increases over time. Tremor frequency decreases with increasing age. An 8 12 Hz tremor is seen in young adults and a 6 8 Hz tremor is seen in the elderly. Although ET is progressive, no association has been found between age of onset and severity of disability.
- Disability stemming from ET is common. Significant changes in livelihood and socializing are reported by 85% of individuals with ET, and 15% report being seriously disabled due to ET. Decreased quality of life results from both loss of function and embarrassment. In a study of hereditary ET, 60% did not seek employment, 25% changed jobs or took early retirement, 65% did not dine out, 30% did not attend social functions, and 20% stopped driving.
- Systems for treating a movement disorder include a system control unit configured to be implanted at least partially within a patient and to generate at least one stimulus in accordance with one or more stimulation parameters adjusted to treat the movement disorder. The systems further include a programmable memory unit in communication with the system control unit and programmed to store the one or more stimulation parameters to at least partially define the stimulus such that the stimulus is configured to treat the movement disorder. A means for applying the stimulus to one or more stimulation sites within the patient is operably connected to the system control unit.
- The accompanying drawings illustrate various embodiments of the principles described herein and are a part of the specification. The illustrated embodiments are merely examples and do not limit the scope of the disclosure.
-
FIG. 1A depicts the dorsal surface of the brain stem according to principles described herein. -
FIGS. 1B and 1C are section views through the brain stem depicted inFIG. 1A according to principles described herein. -
FIG. 2A depicts the medial surface of the brain according to principles described herein. -
FIG. 2B is a coronal section view of the brain ofFIG. 2A according to principles described herein. -
FIGS. 3A, 3B , and 3C show some possible configurations of an implantable microstimulator of the present invention according to principles described herein. -
FIG. 4 illustrates a lateral view of the skull and components of an exemplary system control unit according to principles described herein. -
FIG. 5 illustrates internal and external components of a stimulation system according to principles described herein. -
FIG. 6 illustrates various external components of a system control unit according to principles described herein. -
FIG. 7 depicts a system of implantable devices that communicate with each other and/or with external control/programming devices according to principles described herein. - Throughout the drawings, identical reference numbers designate similar, but not necessarily identical, elements.
- Methods and systems for treating one or more movement disorders are described herein. An implanted stimulator is configured to apply at least one stimulus to a stimulation site within a patient in accordance with one or more stimulation parameters. The stimulus is configured to treat a movement disorder and may include electrical stimulation and/or drug stimulation. As used herein, and in the appended claims, “treating” a movement disorder refers to any amelioration of one or more causes and/or one or more symptoms of the movement disorder.
- In the following description, for purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the present systems and methods. It will be apparent, however, to one skilled in the art that the present systems and methods may be practiced without these specific details. Reference in the specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. The appearance of the phrase “in one embodiment” in various places in the specification are not necessarily all referring to the same embodiment.
- The pathophysiology of many movement disorders is unknown. For example, the cause of essential tremor (“ET”) is unknown. However, it has been hypothesized that ET is the result of an abnormally functioning central oscillator, which is located in Guillain Mollaret triangle near the brainstem, and involves the inferior olivary nucleus. It is also believed that there is probable involvement of cerebellar-brainstem-thalamic-cortical circuits.
- When Harmaline, a Monoamine Oxidase (MAO) inhibitor, is administered to primates with lesions of ventromedial tegmental tract or lateral cerebellum, an ET-like tremor is produced. In these animals, inferior olivary nucleus neurons file synchronously at the tremor frequency. C-2-deoxyglucose PET studies demonstrate hypermetabolism in the inferior olivary nuclei of rats and cats with harmaline-induced tremor. Stimulation of the vagus nerve helped resolve tremor in rats with harmaline-induced tremor.
- In patients with ET, [18F]-fluorodeoxyglucose PET studies identified increased glucose consumption in the medulla. [15O]-H2O PET studies demonstrate an increase in medullary regional cerebral blood flow (CBF) in subjects with ET, only after the administration of ethanol, and showed bilateral overactivity of cerebellar circuitry.
- The nucleus tractus solitarius (NTS) sends fibers bilaterally to the reticular formation and hypothalamus that are important in the reflex control of cardiovascular, respiratory, and gastrointestinal functions. The NTS also provides input to the dorsal motor nucleus of the vagus that enables the parasympathetic fibers of the vagus nerve to control these reflex responses. The NTS runs the entire length of the medulla oblongata, and the NTS receives somatic sensory input from all cranial nerves, with much of its input coming from the vagus nerve. Since the NTS receives much of its input from the vagus nerve, and since electrical stimulation of the vagus nerve has been demonstrated to be effective in the treatment of an animal model of essential tremor (i.e., for harmaline-induced tremor), then electrical stimulation of the NTS may be effective in the treatment of movement disorders such as essential tremor.
- Patients suffering from tremor and other symptoms may undergo surgery to lesion a part of the brain (e.g., the ventral intermediate (Vim) nucleus of the thalamus the internal segment of the globus pallidus (GPi), or the subthalamic nucleus (STN)), which may afford some relief. However, a lesion is irreversible, and may lead to side effects such as dysarthria or cognitive disturbances. Additionally, lesions generally yield effects on only one side of the body (the contra-lateral side), and bilateral lesions are significantly more likely to produce side effects. Other surgical procedures, such as fetal tissue transplants, are costly and unproven.
- Other areas of the brain exhibit decreased neural activity in some patients with movement disorders. For instance, some Parkinson's disease patients demonstrate decreased neural activity in parts of the caudate and putamen, the external segment of the globus pallidus (GPe), substantia nigra, and/or parts of the thalamus.
- An article published online by Gill, et al. describes delivery of glial cell line-derived neurotrophic factor (GDNF) directly into the putamen of five Parkinson patients in a phase 1 safety trial. [See Gill, et al. “Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.” Nature Medicine epub ahead of print: Mar. 2003, 31.] Baseline positron emission tomography (PET) scans indicated that the posterior segment of the putamen in all patients had low [18F]dopa uptake. After 18 months, PET scans showed a 28% increase in putamen dopamine storage, in contrast to the predicted decline of up to 20% over this period for Parkinson disease patients. The authors note, however, that the exact mechanism by which GDNF works has yet to be established.
- Levy, et al., 2001, present data based on microelectrode recordings from the GPi and the STN during administration of apomorphine, a fast-acting non-selective D1-dopamine and D2-dopamine receptor agonist. [See Levy, et al. “Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease.” Journal of Neurophvsiology 2001 July;86(1):249-60.] Apomorphine has previously been demonstrated to ameliorate symptoms of Parkinson's disease. In the study, the authors administered doses of apomorphine sufficient to produce relief of Parkinson symptoms, but not sufficient to induce common side effects such as dyskinetic movements. Following baseline microelectrode recordings, apomorphine was administered. The spontaneous discharge of neurons encountered before, during, and after the effect of apomorphine had waned was also sampled.
- A reduction in Parkinson symptoms (e.g., limb tremor) was observed in patients when apomorphine reached therapeutic levels. Apomorphine significantly decreased the overall firing rates of GPi neurons, but there was no change in the overall firing rate of neurons in the STN. Concurrent with a reduction in limb tremor, the percentage of cells with tremor-related activity (i.e., tremor cells) was found to be significantly reduced from 19% to 6% in the STN and from 14% to 0% in the GPi following apomorphine administration. Apomorphine also decreased the firing rate of STN tremor cells. As the effects of apomorphine waned, the overall firing rates of GPi neurons increased. In contrast to the findings above, Stefani, et al., 2002, found that administration of apomorphine did indeed reduce the firing rates of all STN cells in patients with Parkinson's disease, concurrent with a reduction in the clinical symptoms of Parkinson's disease. [See Sefani, et al., “Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the ‘indirect pathway’.” Clinical Neurophvsioloqy August 2002;113(1):91-100.] These results suggest that the discharge frequency of the GPi and possibly of the STN is a measurable quantity that correlates with the clinical efficacy of medication.
- While not previously observed, this GPi discharge frequency phenomenon may occur during deep brain stimulation (DBS) as well. The subthalamic nucleus (STN) is believed to demonstrate increased neurotransmitter release in Parkinson's disease, and it responds to deep brain stimulation. Thus, it may demonstrate a similar discharge frequency phenomenon as the GPi. Since the Vim nucleus of the thalamus also responds to deep brain stimulation, it may also demonstrate a similar discharge frequency phenomenon.
- In addition, high frequency chronic electrical stimulation (i.e., frequencies above 100 Hz) of certain areas of the brain has been demonstrated to be as efficacious as producing a lesion in any one of those areas. In contrast to ablation surgery, chronic electrical stimulation is reversible. Additionally, stimulation parameters may be adjusted to minimize side effects while maintaining efficacy; such “fine tuning” is unavailable when producing a lesion.
- An implantable chronic stimulation device for DBS is available and similar systems are under development. DBS has proven to be effective for treating some patients with movement disorders; however, the current procedure is highly invasive, and the initial surgery for placement of the available system requires essentially an entire day. These systems require the power source and stimulation electronics to be implanted far from the electrodes, generally in the chest or elsewhere in the trunk of the body. These bulky systems therefore require extensive invasive surgery for implantation, and breakage of the long leads is highly likely. In addition, current DBS systems for movement disorders use no feedback for regulation of stimulation.
-
FIG. 1A depicts the dorsal surface of the brain stem, andFIGS. 1B and 1C are section views through the brain stem depicted inFIG. 1A , whileFIG. 2A depicts the medial surface of the brain andFIG. 2B is a coronal section view of the brain ofFIG. 2A .FIG. 1B shows the location of the nucleus tractus solitarius (NTS) 100.FIG. 1C shows the locations of the substantia nigra pars reticulata 102 (as seen in the figure, the substantia nigra pars reticulata is included in the substantia nigra, as is the substantia nigra pars compacta), the ventral intermediate (Vim)thalamic nucleus 104, thepallidosubthalamic tracts 106, and the pallido-thalamic axons 107 (as seen in the figure, pallido-thalamic axons are found in the lenticular fasciculus and the ansa lenticularis).FIG. 2B shows the location of the putamen toGPe fibers 108.FIGS. 1C and 2B show the locations of the internal globus pallidus (GPi) 110, the external globus pallidus (GPe) 112, theputamen 116, and the subthalamic nucleus (STN) 120. - It is believed that applying a stimulus to one or more of the above-mentioned areas may be useful in treating one or more movement disorders. As mentioned, “treating” a movement disorder refers to any amelioration or prevention of one or more causes, symptoms, and/or sequelae of the movement disorder. Consequently, an SCU, also referred to herein as a stimulator, may be implanted within a patient to deliver a stimulus to one or more stimulation sites within the patient to treat one or more nerve compression syndromes. In some examples, the stimulus may include an electrical stimulation current and/or one or more drugs that are infused into the stimulation site.
- The one or more stimulation sites referred to herein, and in the appended claims, may include, but are not limited to, the NTS, the ventral intermediate thalamic nucleus, the GPi, the GPe, the STN, the pallidosubthalamic tracts, the substantia nigra pars reticulate, the pallido-thalamic axons, the putamen to GPe fibers, the subthalamo-pallidal fibers, the putamen to GPi fibers, the cerebellum, and/or any other suitable location within the brain. In some examples, as will be described in more detail below, the stimulus is configured to adjust the level of neural activity in one or more of these areas, and thereby treat one or more movement disorders.
- For instance, for patients who demonstrate increased neural activity of ventral intermediate thalamic nucleus, pallido-thalamic axons, putamen to GPe fibers, GPi, STN, subthalamo-pallidal fibers, and/or the cerebellum, inhibitory stimulation may be applied to one or more of these areas in order to treat one or more movement disorders. On the other hand, for patients who exhibit decreased neural activity of NTS, substantia nigra pars reticulata, pallido-subthalamic tracts, GPe, putamen, and/or putamen to GPi fibers, excitatory stimulation may be applied to one or more of these areas in order to treat one or more movement disorders. As used herein, the terms “stimulate”, “stimulation”, and “stimulating” refer to infusion of one or more drugs at the stimulation site and/or applying one or more electrical current pulses to the stimulation site.
- As such, infusion parameters and/or electrical current parameters are sometimes referred to herein as simply stimulation parameters, which parameters may include amplitude, volume, pulse width, infusion rate, and the like. Similarly, stimulation pulses may be pulses of electrical energy and/or pulses of drugs infused by various means and rates of infusion, such as intermittent infusion, infusion at a constant rate, and bolus infusion.
- Herein, stimulating drugs may include medications and other pharmaceutical compounds, anesthetic agents, synthetic or natural hormones, neurotransmitters, interleukins, cytokines, lymphokines, chemokines, growth factors (e.g., glial cell line-derived neurotrophic factor (GDNF), brain cell line-derived neurotrophic factor (BDNF)), and other intracellular and intercellular chemical signals and messengers, and the like. Certain neurotransmifters, hormones, and other drugs are excitatory for some tissues, yet are inhibitory to other tissues. Therefore, where, herein, a drug is referred to as an “excitatory” drug, this means that the drug is acting in an excitatory manner, although it may act in an inhibitory manner in other circumstances and/or locations. Similarly, where an “inhibitory” drug is mentioned, this drug is acting in an inhibitory manner, although in other circumstances and/or locations, it may be an “excitatory” drug. In addition, stimulation of an area herein may include stimulation of cell bodies and axons in the area.
- A number of drugs have demonstrated efficacy in the treatment of Parkinson's disease. For example, a drug referred to as “Levodopa” is effective in some patients with Parkinson's disease. Levodopa is typically administered with a dopa decarboxylase inhibitor in order to prevent systemic side effects.
- Patent Cooperation Treaty publication WO 00/38669(A2), which is incorporated herein by reference in its entirety, teaches administration of naloxone to the substantia nigra for the prevention of neural degeneration. (Naloxone is an opiate antagonist.) Since degeneration of the substantia nigra is the primary pathology of Parkinson's disease, administration of naloxone to the substantia nigra may be therapeutic.
- In some examples, the SCU includes an implantable signal generator coupled to one or more electrodes and/or an implantable pump connected to a catheter(s). These systems deliver electrical stimulation and/or one or more stimulating drugs to specific areas in the brain. One or more electrodes are surgically implanted in the brain to provide electrical stimulation, and/or one or more catheters are implanted in the brain to infuse the stimulating drug(s).
- In some examples, the SCU includes an implantable microstimulator, such as a BION® microstimulator (Advanced Bionics® Corporation, Valencia, Calif.). Exemplary microstimulators will be described in connection with
FIGS. 3A-3C . Various details associated with the manufacture, operation, and use of implantable microstimulators are disclosed in U.S. Pat. Nos. 5,193,539; 5,193,540; 5,312,439; 6,185,452; 6,164,284; 6,208,894; and 6,051,017. All of these listed patents are incorporated herein by reference in their respective entireties. - As shown in
FIGS. 3A, 3B , and 3C, anexemplary microstimulator SCU 160 may include a narrow,elongated capsule 152 containingelectronic circuitry 154 connected toelectrodes electrodes 172 and/or 172′ may be disposed on the outer surface or case of theSCU 160 and/or arranged on a catheter or at the end of a lead, as described below. - In some examples,
electrodes microstimulator SCU 160 are possible. - Certain configurations of
implantable microstimulator SCU 160 are sufficiently small to permit placement in or adjacent to the structures to be stimulated. For instance, in these configurations,capsule 152 may have a diameter substantially equal to or less than 4-5 millimeters and a length substantially equal to or less than 25-35 mm. The shape of the microstimulator may be determined by the structure of the desired target, the surrounding area, and the method of implantation. A thin, elongated cylinder with electrodes at the ends, as shown inFIGS. 3A, 3B , and 3C, is one possible configuration, but other shapes, such as cylinders, disks, spheres, and helical structures, are possible, as are additional electrodes, infusion outlets, leads, and/or catheters. - 3
Microstimulator SCU 160, when certain configurations are used, may be implanted with a surgical tool such as a tool specially designed for the purpose, or with a hypodermic needle, or the like. Alternatively,microstimulator SCU 160 may be implanted via conventional surgical methods (e.g., via a small incision), or may be placed using endoscopic or laparoscopic techniques. - In some examples, the
microstimulator SCU 160 may be implanted with the aid of a stereotactic frame via a minimal surgical procedure (e.g., through a small burr hole) adjacent to or at the sites mentioned above. As mentioned, themicrostimulator SCU 160 may be sufficiently small to be able to fit through a conventional burr hole in the skull. Alternative implantation methods include CT scan or ultrasound image guidance. - The external surfaces of
microstimulator SCU 160 may advantageously be composed of biocompatible materials.Capsule 152 may be made of, for instance, glass, ceramic, or other material that provides a hermetic package that will exclude water vapor but permit passage of electromagnetic fields used to transmit data and/or power.Electrodes - In some examples, the
microstimulator SCU 160 may include two leadless electrodes disposed on an outer surface or case thereof. Alternatively, either or bothelectrodes microstimulator SCU 160, while allowing most elements of the microstimulator to be located in a more surgically convenient site. This minimizes the distance traversed and the surgical planes crossed by the device and any lead(s). - In some examples, as depicted in
FIG. 4 , theSCU 160 may be implanted beneath the scalp, such as in a surgically-created shallow depression or opening in theskull 140. The surgically-created shallow depression or opening may be located in theparietal bone 141, thetemporal bone 142, and/or thefrontal bone 143. In some examples, theSCU 160 is configured to conform to the profile of surrounding tissue(s) and/or bone(s). This may minimize pressure applied to the skin or scalp, which pressure may result in skin erosion or infection. - As shown in
FIG. 4 , one or more electrode leads 170 and/orcatheters 180 attached toSCU 160 run subcutaneously, for instance, in a surgically-created shallow groove(s) in the skull, to an opening(s) in the skull, and pass through the opening(s) into or onto the brain parenchyma and surrounding tissue. Recessed placement of the SCU and the lead(s) and/or catheter(s) may decrease the likelihood of erosion of the overlying skin, and may minimize any cosmetic impact. - As shown in
FIG. 4 , electrode(s) 172 are carried onlead 170 having a proximal end coupled toSCU 160. The lead contains insulated wires electrically connectingelectrodes 172 toSCU 160.SCU 160 containselectrical components 154 that produce electrical stimulation pulses that travel through the wires oflead 170 and are delivered toelectrodes 172, and thus to thetissue surrounding electrodes 172. To protect the electrical components insideSCU 160, some or all of the case of the SCU may be hermetically sealed. For additional protection against, e.g., impact, the case may be made of metal (e.g. titanium) or ceramic, which materials are also, advantageously, biocompatible. In addition,SCU 160 may be configured to be Magnetic Resonance Imaging (MRI) compatible. - In some alternatives, the electrical stimulation may be provided as described in International Patent Application Serial Number PCT/US01/04417 (the '417 application), filed Feb. 12, 2001, and published Aug. 23, 2001 as WO 01/60450, which application is incorporated herein by reference in its entirety.
- In the case of treatment alternatively or additionally constituting drug infusion, SCU 160 (which herein refers to IPGs, implantable pumps, IPG/pump combinations, microstimulators for drug and/or electrical stimulation, and/or other alternative devices described herein) may contain at least one
pump 162 for storing and dispensing one or more drugs through outlet(s) 182/182′ and/or catheter(s) 180/180′ into a predetermined site(s) in the brain tissue. When a catheter is used, it includes at least oneinfusion outlet 182, usually positioned at least at a distal end, while a proximal end of the catheter is connected toSCU 160. - In some examples, as depicted in
FIG. 5 , at least onelead 170 may be coupled toSCU 160 via asuitable connector 168. Additional leads 170′ and/or catheter(s) 180′ may be attached toSCU 160 as may serve a particular application. Hence,FIG. 5 shows (in phantom lines) asecond catheter 180′, and asecond lead 170′, havingelectrodes 172′ thereon, also attached toSCU 160. Similarly, theSCUs 160 ofFIGS. 3A, 3B , and 3C haveoutlets electrodes - In some examples, the
catheters 160 and/or leads 170 are substantially cylindrical. In some alternative examples, one or more of theleads 170 may be paddle-shaped.Electrodes leads - In some examples,
SCU 160 is programmable to produce either monopolar electrical stimulation, e.g., using the SCU case as an indifferent electrode, or bipolar electrical stimulation, e.g., using one of the electrodes of the electrode array as an indifferent electrode. In some examples, theSCU 160 may have at least four channels and drive up to sixteen or more electrodes. - As shown in
FIG. 5 ,SCU 160 may additionally or alternatively includeelectronic circuitry 154 for receiving data and/or power from outside the body by inductive radio frequency (RF), or other electromagnetic coupling. To this end,electronic circuitry 154 may include an inductive coil for receiving and transmitting RF data and/or power, an integrated circuit (IC) chip for decoding and storing stimulation parameters and generating stimulation pulses (either intermittent or continuous), and additional discrete electronic components required to complete the electronic circuit functions, e.g. capacitor(s), resistor(s), coil(s), and the like. - In some examples,
electronic circuitry 154 includes a processor and/or other components configured to generate one or more stimulation pulses that are applied to apatient 208 throughelectrodes 172 in accordance with one or more stimulation parameters stored in aprogrammable memory unit 164. Additionally or alternatively, the processor may be configured to control stimulation parameters associated with drug stimulation. For example, the processor may be configured to cause theSCU 160 to vary the rate of infusion (e.g., intermittent infusion, infusion at a constant rate, and bolus infusion). - As mentioned,
SCU 160 may also include aprogrammable memory 164 for storing one or more sets of data and/or stimulation parameters. Among other things,memory 164 may allow electrical and/or drug stimulation to be adjusted to settings that are safe and efficacious with minimal discomfort for each individual. Specific parameters may provide therapeutic advantages for various types and severities of movement disorders. For instance, some patients may respond favorably to intermittent stimulation, while others may require continuous treatment for relief. In some examples, electrical and drug stimulation parameters are controlled independently, e.g., continuous electrical stimulation and no drug stimulation. However, in some instances, they may advantageously be coupled, e.g., electrical stimulation may be programmed to occur only during drug infusion. - In addition, different stimulation parameters may have different effects on neural tissue. Therefore, parameters may be chosen to target specific neural populations and/or to exclude others, or to increase neural activity in specific neural populations and/or to decrease neural activity in others. For example, relatively low levels of stimulation current (e.g., anywhere between about 0.05 mA to about 5.0 mA) are likely to recruit only relatively large diameter fibers. In some examples, the stimulation may be configured to selectively increase neural activity of only the relatively large diameter fibers of
NTS 100. Relatively low amplitude electrical current pulses are likely to produce such selective excitation. - As another example, relatively low frequency neurostimulation (i.e., less than about 100-150 Hz) typically has an excitatory effect on surrounding neural tissue, leading to increased neural activity, whereas relatively high frequency neurostimulation (i.e., greater than about 100-150 Hz) may have an inhibitory effect, leading to decreased neural activity. Similarly, excitatory neurotransmitters (e.g., glutamate, dopamine, norepinephrine, epinephrine, acetylcholine, serotonin), agonists thereof (e.g., glutamate receptor agonist(s), apomorphine), and agents that act to increase levels of an excitatory neurotransmitter(s) (e.g., edrophonium, Mestinon) generally have an excitatory effect on neural tissue, while inhibitory neurotransmitters (e.g., dopamine, glycine, and gamma-aminobutyric acid, a.k.a. GABA), agonists thereof (e.g., muscimol, apomorphine), and agents that act to increase levels of an inhibitory neurotransmitter(s) generally have an inhibitory effect. (Dopamine acts as an excitatory neurotransmitter in some locations and circumstances, and as an inhibitory neurotransmitter in other locations and circumstances.) However, antagonists of inhibitory neurotransmitters (e.g., bicuculline) and agents that act to decrease levels of an inhibitory neurotransmitter(s) have been demonstrated to excite neural tissue, leading to increased neural activity. Similarly, excitatory neurotransmitter antagonists (e.g. prazosin, metoprolol, atropine, benztropine) and agents that decrease levels of excitatory neurotransmitter(s) (e.g., acetylcholinesterase, Group II metabotropic glutamate receptor (mGluR) agonists such as DCG-IV) may inhibit neural activity.
- The
SCU 160 may also include apower source 166. In some examples, thepower source 166 may include a self-contained power source utilizing any suitable means of generation or storage of energy (e.g., a primary battery, a replenishable or rechargeable battery such as a lithium ion battery, an electrolytic capacitor, a super- or ultra-capacitor, or the like), a rechargeable power source, and/or means receiving power from an external power source. In cases where thepower source 166 includes a rechargeable power source, theSCU 160 may be configured to receive power from an external battery charging system (EBCS) 192, typically through aninductive link 194. - In some examples, the
SCU 160 operates independently. Alternatively, theSCU 160 operates in a coordinated manner with other SCU(s), other implanted device(s), and/or other device(s) external to the patient's body. For instance, anSCU 160 may control or operate under the control of another implanted SCU(s), other implanted device(s), and/or other device(s) external to the patient's body. An SCU may communicate with other implanted SCUs, other implanted devices, and/or devices external to a patient's body via, e.g., an RF link, an ultrasonic link, a thermal link, and/or an optical link. Specifically, an SCU may communicate with an external remote control (e.g., patient and/or physician programmer) that is configured to send commands and/or data to an SCU and that may also be capable of receiving commands and/or data from an SCU. - For example, the
SCU 160 may be activated, deactivated, programmed, and/or tested through a hand held programmer (HHP) 200 (which may also be referred to as a patient programmer and may be, but is not necessarily, hand held), a clinician programming system (CPS) 202 (which may also be hand held), and/or a manufacturing and diagnostic system (MDS) 204 (which may also be hand held).HHP 200 may be coupled toSCU 160 via anRF link 195. Similarly,MDS 204 may be coupled toSCU 160 via anotherRF link 196. In a like manner,CPS 202 may be coupled toHHP 200 via an infra-red link 197; andMDS 204 may be coupled toHHP 200 via another infra-red link 198. Other types of telecommunicative links, other than RF or infra-red may also be used for this purpose. Through these links,CPS 202, for example, may be coupled throughHHP 200 toSCU 160 for programming or diagnostic purposes.MDS 204 may also be coupled toSCU 160, either directly throughRF link 196, or indirectly throughIR link 198,HHP 200, and RF link 195. - External components for programming and/or providing power to the
SCU 160 are also illustrated inFIG. 6 . When communication with such anSCU 160 is desired,patient 208 is positioned on or nearexternal appliance 220, which appliance contains one or moreinductive coils 222 or other means of communication (e.g., RF transmitter and receiver).External appliance 220 is connected to or is a part of externalelectronic circuitry appliance 230 which may receivepower 232 from a conventional power source.External appliance 230 contains manual input means 238, e.g., a keypad, whereby thepatient 208 or acaregiver 242 may request changes in electrical and/or drug stimulation parameters produced during the normal operation ofSCU 160. In these examples, manual input means 238 includes various electromechanical switches and/or visual display devices that provide the patient and/or caregiver with information about the status and prior programming ofSCU 160. - In some examples, the
patient 208switches SCU 160 on and off by use ofcontroller 210, which may be handheld.SCU 160 is operated bycontroller 210 by any of various means, including sensing the proximity of a permanent magnet located incontroller 210, sensing RF transmissions fromcontroller 210, or the like. - Additionally or alternatively, external
electronic appliance 230 is provided with an electronic interface means 246 for interacting with other computing means 248, such as by a serial interface cable or infrared link to a personal computer or to a telephone modem or the like. Such interface means 246 may permit a clinician to monitor the status of the implant and prescribe new stimulation parameters from a remote location. - The external appliance(s) may be embedded in a cushion, pillow, hat, or the like. Other possibilities exist, including a head band, patch, or other structure(s) that may be affixed to the patient's body or clothing. External appliances may include a package that can be, e.g., worn on the belt, may include an extension to a transmission coil affixed, e.g., with a Velcro® band or an adhesive, or may be combinations of these or other structures able to perform the functions described herein.
- In order to determine the strength and/or duration of electrical stimulation and/or the amount and/or type(s) of stimulating drug(s) required to produce the desired effect, a patient's response to and/or need for treatment may be sensed. For example, head acceleration, electrical activity of the brain (e.g., EEG or discharge frequency of a neural population), nerve activity (e.g., ENG), muscle activity (e.g., limb EMG), or other activity may be sensed.
- For instance, one or more electrodes may be used for recording electrical signals from the brain. Recording of the neural activity of one or more areas being stimulated, e.g.,
NTS 100 or pallido-subthalamic tracts 106, may be performed in order to determine the discharge frequency of the neural population. This sensing may occur during stimulation or during a temporary suspension of stimulation. In some examples, the amplitude of stimulation is increased if the discharge frequency is above a programmable threshold frequency, and the amplitude of stimulation is decreased if the discharge frequency is less than another programmable threshold frequency. The two programmable threshold frequencies may be the same or may be different in order to achieve hysteresis. - In another example, one or more accelerometers may be used for sensing acceleration of the head. Rhythmic acceleration of the head is seen in head tremor. Thus, the amplitude of rhythmic head acceleration is an indicator of the amplitude of head tremor. The amplitude of stimulation is increased if the amplitude of rhythmic head acceleration is above a programmable threshold amplitude, and the amplitude of stimulation is decreased if the amplitude of rhythmic head acceleration is below a programmable threshold amplitude. The two programmable threshold amplitudes may be the same or may be different in order to achieve hysteresis. This sensing may advantageously be used for patients with significant head tremor as a component of their movement disorder, such as certain patients with benign essential tremor.
- Other measures of the state of the patient may additionally or alternatively be sensed. For instance, one or more neurotransmitter levels, their associated breakdown product levels, hormone levels, or other substances, such as dopamine levels, interleukins, cytokines, lymphokines, chemokines, growth factors, electrolytes, enzymes, medication, and/or other drug levels, or levels of any other bloodborne substance(s), and/or changes in one or more of these may be sensed, using, e.g., one or more Chemically Sensitive Field-Effect Transistors (CHEMFETs) such as Enzyme-Selective Field-Effect Transistors (ENFETs) or Ion-Sensitive Field-Effect Transistors (ISFETs, as are available from Sentron CMT of Enschede, The Netherlands). For example, when electrodes of
SCU 160 are implanted in or adjacent to pallido-subthalamic tracts 106, a stimulating electrode ofSCU 160, or other sensing means contained in the electrode lead, catheter, IPG, microstimulator, or any part of the system may be used to sense changes in neural firing frequency of the pallido-subthalamic tracts 106 resulting from the electrical and/or drug stimulation applied to the pallido-subthalamic tracts 106. (As used herein, “adjacent” or “near” means as close as reasonably possible to targeted tissue, including touching or even being positioned within the tissue, but in general, may be as far as about 150 mm from the target tissue.) - Alternatively, an SCU dedicated to sensory processes communicates with an SCU providing stimulation pulses. The
implanrt circuitry 154 may, if necessary, amplify and transmit these sensed signals, which may be digital or analog. Other methods of determining the required electrical and/or drug stimulation include measuring impedance, acidity/alkalinity (via a pH sensor), muscle EMG, head or limb acceleration (e.g., via accelerometer), EEG, ENG, other methods mentioned herein, and others that will be evident to those of skill in the field upon review of the present disclosure. The sensed information may be used to control stimulation parameters in a closed-loop manner. - For instance, in some examples, a first and second “SCU” are provided. The second “SCU” periodically (e.g. once per minute) records firing rate of neurons in GPi 110 (or the level of a substance, e.g., dopamine or L-Dopa, or an amount of electrical activity, etc.), which it transmits to the first SCU. The first SCU uses the sensed information to adjust electrical and/or drug stimulation parameters according to an algorithm programmed, e.g., by a physician. For example, the amplitude and/or frequency of electrical stimulation may be increased in response to increased firing rate of neurons in
GPi 110. In some alternative examples, one SCU performs both the sensing and stimulating functions. - While an
SCU 160 may also incorporate means of sensing symptoms or other prognostic or diagnostic indicators of movement disorders, e.g., via sensing of tremor (e.g., via accelerometer), sensing of dopamine or dopamine agonist levels (e.g., L-dopa), and/or sensing of neural electrical activity (e.g., firing rate of neurons in pallido-subthalamic tracts 106), it may alternatively or additionally be desirable to use a separate or specialized implantable device to record and telemeter physiological conditions/responses in order to adjust electrical stimulation and/or drug infusion parameters. This information may be transmitted to an external device, such asexternal appliance 220, or may be transmitted directly to implanted SCU(s) 160. However, in some cases, it may not be necessary or desired to include a sensing function or device, in which case stimulation parameters are determined and refined, for instance, by patient feedback, or the like. - Thus, one or more external appliances may be provided to interact with
SCU 160, and may be used to accomplish at least one or more of the following functions: - Function 1: If necessary, transmit electrical power to the
SCU 160 in order to power theSCU 160 and/or recharge theSCU 160. - Function 2: Transmit data to the
SCU 160 in order to change the stimulation parameters used by theSCU 160. - Function 3: Receive data indicating the state of the SCU 160 (e.g., battery level, drug level, stimulation parameters, etc.).
- By way of example, an exemplary method of treating one or more movement disorders (e.g., Parkinson's disease) may be carried out according to the following sequence of procedures. The steps listed below may be modified, reordered, and/or added to as best serves a particular application.
- 1. A
first SCU 160 is implanted so that itselectrodes 172 and/orinfusion outlet 182 are located in or on or near pallido-subthalamic tracts 106.Electrodes 172′ and/orinfusion outlets 182′ may additionally or alternatively be located in or on or nearNTS 100 or putamen to GPi fibers. - 2. Using Function 2 described above (i.e., transmitting data) of external
electronic appliance 230 andexternal appliance 220,first SCU 160 is commanded to produce a series of excitatory electrical stimulation pulses, possibly with gradually increasing amplitude, and possibly while infusing gradually increasing amounts of an excitatory neurotransmitter, e.g., glutamate, or an inhibitory neurotransmitter antagonist, e.g., bicuculline. - 3. After each stimulation pulse, series of pulses, or at some other predefined interval, any change in, e.g., tremor (sensed, e.g., via accelerometer in limb) resulting from the electrical and/or drug stimulation is sensed, for instance, by one or
more electrodes second SCU 160, preferably amicrostimulator SCU 160, implanted in or on or near a limb(s). These responses may be converted to data and telemetered out to externalelectronic appliance 230. - 4. From the response data received at
external appliance 230 fromsecond SCU 160, or from other assessment, the stimulus threshold for obtaining a response is determined and used by aclinician 242 acting directly 238 or by other computing means 248 to transmit the desired electrical and/or drug stimulation parameters tofirst SCU 160. Alternatively, thesecond SCU 160 uses the response data to determine the stimulation parameters and transmits the parameters tofirst SCU 160. In yet another alternative, thesecond SCU 160 transmits the response data tofirst SCU 160, which uses the response data directly to determine the stimulation parameters. Finally, some combination of the above may be used. - 5. When
patient 208 desires to invoke electrical stimulation and/or drug infusion,patient 208 employscontroller 210 to setfirst SCU 160 in a state where it delivers a prescribed stimulation pattern from a predetermined range of allowable stimulation patterns. - 6. To cease electrical and/or drug stimulation,
patient 208 employscontroller 210 to turn offfirst SCU 160 and possibly alsosecond SCU 160. - 7. Periodically, the patient or caregiver recharges the power source/
storage device 166 of first and/orsecond SCU 160. - In another example, a treatment for movement disorders, e.g., essential tremor, may be carried out according to the following sequence of procedures:
- 1. An
SCU 160 is implanted so that itselectrodes 172 and possibly alsoinfusion outlet 182 are located in or on or nearNTS 100. - 2.
First SCU 160 is commanded to produce a series of excitatory electrical stimulation pulses, possibly with gradually increasing amplitude, and possibly while infusing gradually increasing amounts of an excitatory neurotransmitter, e.g., glutamate, or an inhibitory neurotransmitter antagonist, e.g., bicuculline. - 3. After each stimulation pulse, series of pulses, or at some other predefined interval, any change in movement disorder signs and symptoms, e.g., change in neural firing rate in
GPi 110, resulting from the electrical and/or drug stimulation is sensed, for instance, by one or more of theelectrodes 172 ofSCU 160. These responses are converted to data and telemetered out to externalelectronic appliance 230. - 4. From the response data received at
external appliance 230 fromSCU 160, or from other assessment, the stimulus threshold for obtaining a response is determined and is used by aclinician 242 acting directly 238 or by other computing means 248 to transmit the desired electrical and/or drug stimulation parameters to SCU. 160. - 5. When
patient 208 desires to invoke electrical stimulation and/or drug infusion,patient 208 employscontroller 210 to setSCU 160 in a state where it delivers a prescribed stimulation pattern from a predetermined range of allowable stimulation patterns. - 6. To cease electrical and/or drug stimulation,
patient 208 employscontroller 210 to turn offSCU 160. - 7. Periodically, the patient or caregiver recharges the power source/
storage device 166 ofSCU 160. - For the treatment of any of the various types and severities of movement disorders, it may be desirable to modify or adjust the algorithmic functions performed by the implanted and/or external components, as well as the surgical approaches, in ways that would be obvious to skilled practitioners of these arts. For example, in some situations, it may be desirable to employ more than one
SCU 160, each of which could be separately controlled by means of a digital address. Multiple channels and/or multiple patterns of electrical and/or drug stimulation might thereby be programmed by the clinician and controlled by the patient in order to, for instance, deal with complex or multiple symptoms or conditions, such as Parkinson's disease coupled with side effects from medication, e.g., dyskinesia. - In some examples a group of two or
more SCUs 160 is controlled via closed-loop operation. A need for and/or response to stimulation is sensed viaSCU 160, or by an additional SCU (which may or may not be dedicated to the sensing function), or by another implanted or external device. If necessary, the sensed information is transmitted toSCU 160. In some cases, the sensing and stimulating are performed by one SCU. In some examples, the parameters used bySCU 160 are automatically adjusted based on the sensed information. Thus, the electrical and/or drug stimulation parameters are adjusted in a closed-loop manner to provide stimulation tailored to the need for and/or response to the electrical and/or drug stimulation. - For instance, as shown in the example of
FIG. 7 , afirst SCU 160, implanted beneath the skin of thepatient 208, provides a first medication or substance; asecond SCU 160′ provides a second medication or substance; and athird SCU 160″ provides electrical stimulation viaelectrodes control lines FIG. 7 . That is, theexternal controller 250 controls the operation of each of the implanteddevices - In some examples wherein the
SCU 160 is configured to infuse one or more drugs at a stimulation site, theSCU 160 may incorporate communication means for communicating with one or more external or site-specific drug delivery devices, and, further, may have the control flexibility to synchronize and control the duration of drug delivery. The associated drug delivery device typically provides a feedback signal that lets the control device know it has received and understood commands. The communication signal between the implantedSCU 160 and the drug delivery device may be encoded to prevent the accidental or inadvertent delivery of drugs by other signals. - In some examples, the electrical and/or drug stimulation decreases activity of one or more areas of the brain that exhibit chronic increased activity, relative to control subjects, in patients experiencing a movement disorder(s). These areas may include one or more of the pallido-
thalamic axons 107, putamen toGPe fibers 108, and/or subthalamo-pallidal fibers. Such inhibitory stimulation is likely to be produced by relatively high-frequency electrical stimulation (e.g., greater than about 100-150 Hz), an excitatory neurotransmitter antagonist(s) (e.g. prazosin, metoprolol, atropine), an inhibitory neurotransmitter(s) (e.g., GABA), an agonist thereof, an agent that increases the level of an inhibitory neurotransmitter, an agent that decreases the level of an excitatory neurotransmitter (e.g., DCG-IV), a local anesthetic agent (e.g., lidocaine), and/or an analgesic medication. This stimulation may be applied to one or more of the pallido-thalamic axons 107, putamen toGPe fibers 108, and subthalamo-pallidal fibers to treat movement disorder(s). - In some alternative examples, the electrical and/or drug stimulation increases activity of one or more of those areas of the brain that exhibit chronic decreased activity, relative to control subjects, in patients experiencing a movement disorder(s), thereby treating or preventing such disorder(s) and/or the symptoms and/or pathological consequences thereof. These areas may include one or more of the
NTS 100, pallido-subthalamic tracts 106, and putamen to GPi fibers. Such excitatory stimulation is likely to be produced by relatively low-frequency electrical stimulation (e.g., less than about 100-150 Hz), an excitatory neurotransmitter (e.g., glutamate, acetylcholine), an excitatory cortical neurotransmitter agonist (e.g., glutamate receptor agonist, L-aspartic acid, N-methyl-D-aspartic acid (NMDA), bethanechol, norepinephrine), an inhibitory neurotransmitter antagonist(s) (e.g., bicuculline), an agent that increases the level of an excitatory neurotransmitter (e.g., edrophonium), and/or an agent that decreases the level of an inhibitory neurotransmitter. This stimulation may be applied to one or more of theNTS 100,pallidosubthalamic tracts 106, and putamen to GPi fibers to treat movement disorder(s). - In some examples, the stimulation selectively increases neural activity of the relatively large diameter fibers of the nucleus tractus solitarius (NTS 100). Relatively low amplitude (e.g., about 0.05 mA to about 5.0 mA) electrical current pulses are likely to produce such selective excitation.
- In some examples, one or more stimulating drugs, possibly in combination with electrical stimulation, are infused into the brain. For instance, a growth factor, such as glial cell line-derived neurotrophic factor (GDNF) may be infused into the
putamen 116, possibly while providing electrical stimulation as described above. Other stimulating drugs are described previously herein and include brain cell line-derived neurotrophic factor (BDNF), naloxone, and levodopa. - In some examples, sensing means described earlier may be used to orchestrate first the activation of SCU(s) targeting an area(s) of the brain, and then, when appropriate, SCU(s) targeting another area(s) and/or by different means. Alternatively, this orchestration may be programmed, and not based on a sensed condition.
- The preceding description has been presented only to illustrate and describe embodiments of the invention. It is not intended to be exhaustive or to limit the invention to any precise form disclosed. Many modifications and variations are possible in light of the above teaching.
Claims (22)
1. A system for treating a movement disorder, said system comprising:
a system control unit configured to be implanted entirely within the brain of a patient and to generate at least one stimulus in accordance with one or more stimulation parameters adjusted to treat said movement disorder;
a programmable memory unit in communication with said system control unit and programmed to store said one or more stimulation parameters to at least partially define said stimulus such that said stimulus is configured to increase neural activity of the nucleus tractus solitarius; and
means, operably connected to said system control unit, for applying said stimulus to the nucleus tractus solitarius.
2. The system of claim 1 , wherein said means for applying said at least one stimulus comprises at least one electrode, and wherein said stimulus comprises a stimulation current delivered to the nucleus tractus solitarius via said at least one electrode.
3. The system of claim 2 , wherein said stimulation current comprises one or more stimulation pulses having:
an amplitude substantially greater than or equal to 0.05 milliamps and substantially less than or equal to 5.0 milliamps; and
a frequency substantially less than or equal to 100 Hertz.
4. The system of claim 1 , wherein said means for applying said at least one stimulus comprises at least one infusion outlet, and wherein said stimulus comprises one or more drugs delivered to the nucleus tractus solitarius via said at least one infusion outlet.
5. The system of claim 4 , wherein said one or more drugs comprise at least one or more of an excitatory neurotransmitter, an excitatory cortical neurotransmitter agonist, an inhibitory neurotransmitter antagonist, an agent that increases the level of an excitatory neurotransmitter, and an agent that decreases the level of an inhibitory neurotransmitter.
6. The system of claim 1 , further comprising:
a sensor communicatively coupled to said system control unit and configured to sense at least one condition related to said movement disorder;
wherein said system control unit uses said at least one sensed condition to adjust one or more of said stimulation parameters.
7. A system for treating a movement disorder, said system comprising:
a system control unit configured to be implanted at least partially within a patient and to generate at least one stimulus in accordance with one or more stimulation parameters adjusted to treat said movement disorder;
a programmable memory unit in communication with said system control unit and programmed to store said one or more stimulation parameters to at least partially define said stimulus such that said stimulus is configured to increase neural activity of at least one stimulation site within the brain of said patient; and
means, operably connected to said system control unit, for applying said stimulus to said at least one stimulation site;
wherein said at least one stimulation site comprises at least one or more of the nucleus tractus solitarius, pallido-subthalamic tracts, and putamen to GPi fibers.
8. The system of claim 7 , wherein said means for applying said at least one stimulus comprises at least one electrode, and wherein said stimulus comprises a stimulation current delivered to said at least one stimulation site via said at least one electrode.
9. The system of claim 8 , wherein said stimulation current comprises one or more stimulation pulses having a frequency substantially less than or equal to 100 Hertz.
10. The system of claim 8 , further comprising:
a lead coupled to said system control unit;
wherein said at least one electrode is disposed on a surface of said lead.
11. The system of claim 8 , wherein said at least one electrode is disposed on an outer surface of said system control unit.
12. The system of claim 7 , wherein said means for applying said at least one stimulus comprises at least one infusion outlet, and wherein said stimulus comprises one or more drugs delivered to said at least one stimulation site via said at least one infusion outlet.
13. The system of claim 12 , wherein said means for applying said at least one stimulus further comprises at least one catheter coupling said infusion outlet to said system control unit.
14. The system of claim 7 , further comprising:
a sensor communicatively coupled to said system control unit and configured to sense at least one condition related to said movement disorder;
wherein said system control unit uses said at least one sensed condition to adjust one or more of said stimulation parameters.
15. A system for treating a movement disorder, said system comprising:
a system control unit configured to be implanted at least partially within a patient and to generate at least one stimulus in accordance with one or more stimulation parameters adjusted to treat said movement disorder;
a programmable memory unit in communication with said system control unit and programmed to store said one or more stimulation parameters to at least partially define said stimulus such that said stimulus is configured to decrease neural activity of at least one stimulation site within the brain of said patient; and
means, operably connected to said system control unit, for applying said stimulus to said at least one stimulation site;
wherein said at least one stimulation site comprises at least one or more of the pallido-thalamic axons, putamen to GPe fibers, and subthalamo-pallidal fibers.
16. The system of claim 15 , wherein said means for applying said at least one stimulus comprises at least one electrode, and wherein said stimulus comprises a stimulation current delivered to said at least one stimulation site via said at least one electrode.
17. The system of claim 16 , wherein said stimulation current comprises one or more stimulation pulses having a frequency substantially greater than or equal to 100 Hertz.
18. The system of claim 16 , further comprising:
a lead coupled to said system control unit;
wherein said at least one electrode is disposed on a surface of said lead.
19. The system of claim 16 , wherein said at least one electrode is disposed on an outer surface of said system control unit.
20. The system of claim 15 , wherein said means for applying said at least one stimulus comprises at least one infusion outlet, and wherein said stimulus comprises one or more drugs delivered to said at least one stimulation site via said at least one infusion outlet.
21. The system of claim 20 , wherein said means for applying said at least one stimulus further comprises at least one catheter coupling said infusion outlet to said system control unit.
22. The system of claim 15 , further comprising:
a sensor communicatively coupled to said system control unit and configured to sense at least one condition related to said movement disorder;
wherein said system control unit uses said at least one sensed condition to adjust one or more of said stimulation parameters.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/641,977 US20070100393A1 (en) | 2002-05-24 | 2006-12-19 | Treatment of movement disorders by brain stimulation |
US12/873,170 US8401634B2 (en) | 2002-05-24 | 2010-08-31 | Treatment of movement disorders by brain stimulation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38331602P | 2002-05-24 | 2002-05-24 | |
US10/428,744 US7151961B1 (en) | 2002-05-24 | 2003-05-02 | Treatment of movement disorders by brain stimulation |
US11/641,977 US20070100393A1 (en) | 2002-05-24 | 2006-12-19 | Treatment of movement disorders by brain stimulation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/428,744 Continuation US7151961B1 (en) | 2002-05-24 | 2003-05-02 | Treatment of movement disorders by brain stimulation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/873,170 Continuation US8401634B2 (en) | 2002-05-24 | 2010-08-31 | Treatment of movement disorders by brain stimulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070100393A1 true US20070100393A1 (en) | 2007-05-03 |
Family
ID=37526626
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/428,744 Expired - Fee Related US7151961B1 (en) | 2002-05-24 | 2003-05-02 | Treatment of movement disorders by brain stimulation |
US11/641,977 Abandoned US20070100393A1 (en) | 2002-05-24 | 2006-12-19 | Treatment of movement disorders by brain stimulation |
US12/873,170 Expired - Fee Related US8401634B2 (en) | 2002-05-24 | 2010-08-31 | Treatment of movement disorders by brain stimulation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/428,744 Expired - Fee Related US7151961B1 (en) | 2002-05-24 | 2003-05-02 | Treatment of movement disorders by brain stimulation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/873,170 Expired - Fee Related US8401634B2 (en) | 2002-05-24 | 2010-08-31 | Treatment of movement disorders by brain stimulation |
Country Status (1)
Country | Link |
---|---|
US (3) | US7151961B1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070005752A1 (en) * | 2005-06-29 | 2007-01-04 | Jitendra Chawla | Methods and apparatuses for monitoring attention of a user during a collaboration session |
US20090054955A1 (en) * | 2007-08-20 | 2009-02-26 | Kopell Brian H | Systems and Methods for Treating Neurological Disorders by Light Stimulation |
US7945619B1 (en) | 2004-09-20 | 2011-05-17 | Jitendra Chawla | Methods and apparatuses for reporting based on attention of a user during a collaboration session |
US8504163B1 (en) * | 2006-06-30 | 2013-08-06 | Boston Scientific Neuromodulation Corporation | Cranially mounted stimulation systems and methods |
US8774937B2 (en) | 2009-12-01 | 2014-07-08 | Ecole Polytechnique Federale De Lausanne | Microfabricated surface neurostimulation device and methods of making and using the same |
US8788042B2 (en) | 2008-07-30 | 2014-07-22 | Ecole Polytechnique Federale De Lausanne (Epfl) | Apparatus and method for optimized stimulation of a neurological target |
US8788064B2 (en) | 2008-11-12 | 2014-07-22 | Ecole Polytechnique Federale De Lausanne | Microfabricated neurostimulation device |
US9179875B2 (en) | 2009-12-21 | 2015-11-10 | Sherwin Hua | Insertion of medical devices through non-orthogonal and orthogonal trajectories within the cranium and methods of using |
US9403011B2 (en) | 2014-08-27 | 2016-08-02 | Aleva Neurotherapeutics | Leadless neurostimulator |
US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
US9549708B2 (en) | 2010-04-01 | 2017-01-24 | Ecole Polytechnique Federale De Lausanne | Device for interacting with neurological tissue and methods of making and using the same |
US9925376B2 (en) | 2014-08-27 | 2018-03-27 | Aleva Neurotherapeutics | Treatment of autoimmune diseases with deep brain stimulation |
US10016600B2 (en) | 2013-05-30 | 2018-07-10 | Neurostim Solutions, Llc | Topical neurological stimulation |
US10953225B2 (en) | 2017-11-07 | 2021-03-23 | Neurostim Oab, Inc. | Non-invasive nerve activator with adaptive circuit |
US10966620B2 (en) | 2014-05-16 | 2021-04-06 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
US11077301B2 (en) | 2015-02-21 | 2021-08-03 | NeurostimOAB, Inc. | Topical nerve stimulator and sensor for bladder control |
US11160580B2 (en) | 2019-04-24 | 2021-11-02 | Spine23 Inc. | Systems and methods for pedicle screw stabilization of spinal vertebrae |
US11229789B2 (en) | 2013-05-30 | 2022-01-25 | Neurostim Oab, Inc. | Neuro activator with controller |
US11266830B2 (en) | 2018-03-02 | 2022-03-08 | Aleva Neurotherapeutics | Neurostimulation device |
US11311718B2 (en) | 2014-05-16 | 2022-04-26 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
US11458311B2 (en) | 2019-06-26 | 2022-10-04 | Neurostim Technologies Llc | Non-invasive nerve activator patch with adaptive circuit |
US11730958B2 (en) | 2019-12-16 | 2023-08-22 | Neurostim Solutions, Llc | Non-invasive nerve activator with boosted charge delivery |
US11759238B2 (en) | 2008-10-01 | 2023-09-19 | Sherwin Hua | Systems and methods for pedicle screw stabilization of spinal vertebrae |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151961B1 (en) * | 2002-05-24 | 2006-12-19 | Advanced Bionics Corporation | Treatment of movement disorders by brain stimulation |
US7155279B2 (en) | 2003-03-28 | 2006-12-26 | Advanced Bionics Corporation | Treatment of movement disorders with drug therapy |
US8396565B2 (en) | 2003-09-15 | 2013-03-12 | Medtronic, Inc. | Automatic therapy adjustments |
US7395113B2 (en) | 2004-03-16 | 2008-07-01 | Medtronic, Inc. | Collecting activity information to evaluate therapy |
US8725244B2 (en) | 2004-03-16 | 2014-05-13 | Medtronic, Inc. | Determination of sleep quality for neurological disorders |
US7805196B2 (en) * | 2004-03-16 | 2010-09-28 | Medtronic, Inc. | Collecting activity information to evaluate therapy |
US7717848B2 (en) | 2004-03-16 | 2010-05-18 | Medtronic, Inc. | Collecting sleep quality information via a medical device |
US8209027B2 (en) | 2004-07-07 | 2012-06-26 | The Cleveland Clinic Foundation | System and method to design structure for delivering electrical energy to tissue |
US7346382B2 (en) | 2004-07-07 | 2008-03-18 | The Cleveland Clinic Foundation | Brain stimulation models, systems, devices, and methods |
US20080058893A1 (en) * | 2004-09-20 | 2008-03-06 | Koninklijke Philips Electronics, N.V | Deep Brain Stimulation System |
US8589316B2 (en) | 2009-08-27 | 2013-11-19 | The Cleveland Clinic Foundation | System and method to estimate region of tissue activation |
US7957809B2 (en) | 2005-12-02 | 2011-06-07 | Medtronic, Inc. | Closed-loop therapy adjustment |
EP1998849B1 (en) | 2006-03-24 | 2014-12-24 | Medtronic, Inc. | Collecting gait information for evaluation and control of therapy |
US8280514B2 (en) * | 2006-10-31 | 2012-10-02 | Advanced Neuromodulation Systems, Inc. | Identifying areas of the brain by examining the neuronal signals |
US7949403B2 (en) * | 2007-02-27 | 2011-05-24 | Accelerated Care Plus Corp. | Electrical stimulation device and method for the treatment of neurological disorders |
US9220837B2 (en) | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
CN104069567A (en) | 2007-03-19 | 2014-10-01 | 茵苏莱恩医药有限公司 | Drug delivery device |
US8622991B2 (en) | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
AT10617U1 (en) * | 2007-04-20 | 2009-07-15 | Szeles Jozsef Constantin Dr | DEVICE FOR PUNCTUAL STIMULATION |
US9521955B2 (en) * | 2007-05-03 | 2016-12-20 | Cornell Research Foundtion, Inc. | Subdural electro-optical sensor |
US8103351B2 (en) | 2007-05-07 | 2012-01-24 | Medtronic, Inc. | Therapy control using relative motion between sensors |
US8788055B2 (en) * | 2007-05-07 | 2014-07-22 | Medtronic, Inc. | Multi-location posture sensing |
WO2008157182A1 (en) * | 2007-06-20 | 2008-12-24 | Advanced Neuromodulation Systems, Inc. | Method for selecting electrodes for deep brian or cortical stimulation and pulse generator for deep brian or cortical stimulation |
WO2009036256A1 (en) * | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Injectable physiological monitoring system |
US20090264789A1 (en) * | 2007-09-26 | 2009-10-22 | Medtronic, Inc. | Therapy program selection |
US8380314B2 (en) | 2007-09-26 | 2013-02-19 | Medtronic, Inc. | Patient directed therapy control |
US8121694B2 (en) * | 2007-10-16 | 2012-02-21 | Medtronic, Inc. | Therapy control based on a patient movement state |
US20090118786A1 (en) * | 2007-11-02 | 2009-05-07 | Advanced Bionics Corporation | Automated fitting system for deep brain stimulation |
US8409133B2 (en) | 2007-12-18 | 2013-04-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
CN101925377A (en) | 2008-01-25 | 2010-12-22 | 麦德托尼克公司 | The detection of Sleep stages |
US9220889B2 (en) | 2008-02-11 | 2015-12-29 | Intelect Medical, Inc. | Directional electrode devices with locating features |
US8019440B2 (en) | 2008-02-12 | 2011-09-13 | Intelect Medical, Inc. | Directional lead assembly |
ES2580175T3 (en) | 2008-05-15 | 2016-08-19 | Intelect Medical Inc. | Clinical programmer system and procedure to direct activation volumes |
US9272153B2 (en) | 2008-05-15 | 2016-03-01 | Boston Scientific Neuromodulation Corporation | VOA generation system and method using a fiber specific analysis |
US8515550B2 (en) | 2008-07-11 | 2013-08-20 | Medtronic, Inc. | Assignment of therapy parameter to multiple posture states |
US8249718B2 (en) | 2008-07-11 | 2012-08-21 | Medtronic, Inc. | Programming posture state-responsive therapy with nominal therapy parameters |
US9776008B2 (en) | 2008-07-11 | 2017-10-03 | Medtronic, Inc. | Posture state responsive therapy delivery using dwell times |
US8231556B2 (en) | 2008-07-11 | 2012-07-31 | Medtronic, Inc. | Obtaining baseline patient information |
US9050471B2 (en) | 2008-07-11 | 2015-06-09 | Medtronic, Inc. | Posture state display on medical device user interface |
US8401666B2 (en) | 2008-07-11 | 2013-03-19 | Medtronic, Inc. | Modification profiles for posture-responsive therapy |
US8644945B2 (en) | 2008-07-11 | 2014-02-04 | Medtronic, Inc. | Patient interaction with posture-responsive therapy |
US8504150B2 (en) | 2008-07-11 | 2013-08-06 | Medtronic, Inc. | Associating therapy adjustments with posture states using a stability timer |
US8708934B2 (en) | 2008-07-11 | 2014-04-29 | Medtronic, Inc. | Reorientation of patient posture states for posture-responsive therapy |
US8280517B2 (en) | 2008-09-19 | 2012-10-02 | Medtronic, Inc. | Automatic validation techniques for validating operation of medical devices |
EP2355758A2 (en) | 2008-11-07 | 2011-08-17 | Insuline Medical Ltd. | Device and method for drug delivery |
US8442644B2 (en) | 2008-11-18 | 2013-05-14 | Greatbatch Ltd. | Satellite therapy delivery system for brain neuromodulation |
EP2186541B1 (en) * | 2008-11-18 | 2012-06-27 | Greatbatch Ltd. | Satellite therapy delivery system for brain neuromodulation |
US8685093B2 (en) | 2009-01-23 | 2014-04-01 | Warsaw Orthopedic, Inc. | Methods and systems for diagnosing, treating, or tracking spinal disorders |
US8126736B2 (en) | 2009-01-23 | 2012-02-28 | Warsaw Orthopedic, Inc. | Methods and systems for diagnosing, treating, or tracking spinal disorders |
US20100191100A1 (en) * | 2009-01-23 | 2010-07-29 | Warsaw Orthopedic, Inc. | Methods and systems for diagnosing, treating, or tracking spinal disorders |
US8175720B2 (en) | 2009-04-30 | 2012-05-08 | Medtronic, Inc. | Posture-responsive therapy control based on patient input |
US8231555B2 (en) | 2009-04-30 | 2012-07-31 | Medtronic, Inc. | Therapy system including multiple posture sensors |
US9327070B2 (en) | 2009-04-30 | 2016-05-03 | Medtronic, Inc. | Medical device therapy based on posture and timing |
US9770204B2 (en) * | 2009-11-11 | 2017-09-26 | Medtronic, Inc. | Deep brain stimulation for sleep and movement disorders |
US9357949B2 (en) | 2010-01-08 | 2016-06-07 | Medtronic, Inc. | User interface that displays medical therapy and posture data |
US8579834B2 (en) | 2010-01-08 | 2013-11-12 | Medtronic, Inc. | Display of detected patient posture state |
US9956418B2 (en) | 2010-01-08 | 2018-05-01 | Medtronic, Inc. | Graphical manipulation of posture zones for posture-responsive therapy |
US8758274B2 (en) | 2010-01-08 | 2014-06-24 | Medtronic, Inc. | Automated adjustment of posture state definitions for a medical device |
US9566441B2 (en) | 2010-04-30 | 2017-02-14 | Medtronic, Inc. | Detecting posture sensor signal shift or drift in medical devices |
JP5830090B2 (en) | 2010-06-14 | 2015-12-09 | ボストン サイエンティフィック ニューロモデュレイション コーポレイション | Programming interface for spinal nerve regulation |
US9211411B2 (en) | 2010-08-26 | 2015-12-15 | Medtronic, Inc. | Therapy for rapid eye movement behavior disorder (RBD) |
US20130054270A1 (en) | 2011-03-29 | 2013-02-28 | Boston Scientific Neuromodulation Corporation | Communication interface for therapeutic stimulation providing systems |
US9592389B2 (en) | 2011-05-27 | 2017-03-14 | Boston Scientific Neuromodulation Corporation | Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information |
WO2013023085A2 (en) | 2011-08-09 | 2013-02-14 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing |
EP2741818B1 (en) | 2011-08-09 | 2019-11-20 | Boston Scientific Neuromodulation Corporation | Voa generation system and method using a fiber specific analysis |
WO2013023073A1 (en) | 2011-08-09 | 2013-02-14 | Boston Scientific Neuromodulation Corporation | System and method for weighted atlas generation |
WO2013023076A2 (en) | 2011-08-09 | 2013-02-14 | Boston Scientific Neuromodulation Corporation | Control and/or quantification of target stimulation volume overlap and interface therefor |
WO2013033539A1 (en) | 2011-09-01 | 2013-03-07 | Boston Scientific Neuromodulation Corporation | Methods and system for targeted brain stimulation using electrical parameter maps |
US9081488B2 (en) | 2011-10-19 | 2015-07-14 | Boston Scientific Neuromodulation Corporation | Stimulation leadwire and volume of activation control and display interface |
US9907959B2 (en) | 2012-04-12 | 2018-03-06 | Medtronic, Inc. | Velocity detection for posture-responsive therapy |
US9737719B2 (en) | 2012-04-26 | 2017-08-22 | Medtronic, Inc. | Adjustment of therapy based on acceleration |
WO2014025624A1 (en) | 2012-08-04 | 2014-02-13 | Boston Scientific Neuromodulation Corporation | Techniques and methods for storing and transferring registration, atlas, and lead information between medical devices |
AU2013308910B2 (en) | 2012-08-28 | 2016-10-06 | Boston Scientific Neuromodulation Corporation | Parameter visualization, selection, and annotation interface |
EP2895067B1 (en) * | 2012-09-11 | 2021-02-24 | The Cleveland Clinic Foundation | Evaluation of movement disorders |
US9295838B2 (en) | 2012-10-31 | 2016-03-29 | The Regents Of The University Of California | Methods and systems for treating neurological movement disorders |
US9792412B2 (en) | 2012-11-01 | 2017-10-17 | Boston Scientific Neuromodulation Corporation | Systems and methods for VOA model generation and use |
US9119964B2 (en) | 2013-03-06 | 2015-09-01 | Boston Scientific Neuromodulation Corporation | System for deep brain stimulation employing a sensor for monitoring patient movement and providing closed loop control |
WO2014144029A2 (en) | 2013-03-15 | 2014-09-18 | Boston Scientific Neuromodulation Corporation | Clinical response data mapping |
AU2014348865B2 (en) | 2013-11-14 | 2017-06-01 | Boston Scientific Neuromodulation Corporation | Systems, methods, and visualization tools for stimulation and sensing of neural systems with system-level interaction models |
US9782584B2 (en) | 2014-06-13 | 2017-10-10 | Nervana, LLC | Transcutaneous electrostimulator and methods for electric stimulation |
US10130809B2 (en) | 2014-06-13 | 2018-11-20 | Nervana, LLC | Transcutaneous electrostimulator and methods for electric stimulation |
US9959388B2 (en) | 2014-07-24 | 2018-05-01 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for providing electrical stimulation therapy feedback |
US10265528B2 (en) | 2014-07-30 | 2019-04-23 | Boston Scientific Neuromodulation Corporation | Systems and methods for electrical stimulation-related patient population volume analysis and use |
US10272247B2 (en) | 2014-07-30 | 2019-04-30 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming |
EP3204112A1 (en) | 2014-10-07 | 2017-08-16 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters |
US9956419B2 (en) | 2015-05-26 | 2018-05-01 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
US10780283B2 (en) | 2015-05-26 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
US10441800B2 (en) | 2015-06-29 | 2019-10-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting stimulation parameters by targeting and steering |
WO2017003946A1 (en) | 2015-06-29 | 2017-01-05 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects |
WO2017062378A1 (en) | 2015-10-09 | 2017-04-13 | Boston Scientific Neuromodulation Corporation | System and methods for clinical effects mapping for directional stimulations leads |
US10716942B2 (en) | 2016-04-25 | 2020-07-21 | Boston Scientific Neuromodulation Corporation | System and methods for directional steering of electrical stimulation |
US10776456B2 (en) | 2016-06-24 | 2020-09-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for visual analytics of clinical effects |
US10350404B2 (en) | 2016-09-02 | 2019-07-16 | Boston Scientific Neuromodulation Corporation | Systems and methods for visualizing and directing stimulation of neural elements |
US10780282B2 (en) | 2016-09-20 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters |
WO2018071865A1 (en) | 2016-10-14 | 2018-04-19 | Boston Scientific Neuromodulation Corporation | Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system |
WO2018128949A1 (en) | 2017-01-03 | 2018-07-12 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting mri-compatible stimulation parameters |
WO2018132334A1 (en) | 2017-01-10 | 2018-07-19 | Boston Scientific Neuromodulation Corporation | Systems and methods for creating stimulation programs based on user-defined areas or volumes |
US10625082B2 (en) | 2017-03-15 | 2020-04-21 | Boston Scientific Neuromodulation Corporation | Visualization of deep brain stimulation efficacy |
US11357986B2 (en) | 2017-04-03 | 2022-06-14 | Boston Scientific Neuromodulation Corporation | Systems and methods for estimating a volume of activation using a compressed database of threshold values |
AU2018301355B2 (en) | 2017-07-14 | 2020-10-01 | Boston Scientific Neuromodulation Corporation | Systems and methods for estimating clinical effects of electrical stimulation |
US11596795B2 (en) | 2017-07-31 | 2023-03-07 | Medtronic, Inc. | Therapeutic electrical stimulation therapy for patient gait freeze |
US10960214B2 (en) | 2017-08-15 | 2021-03-30 | Boston Scientific Neuromodulation Corporation | Systems and methods for controlling electrical stimulation using multiple stimulation fields |
EP3684463A4 (en) | 2017-09-19 | 2021-06-23 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11318277B2 (en) | 2017-12-31 | 2022-05-03 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11083895B2 (en) | 2018-03-29 | 2021-08-10 | University Of Washington | Systems and methods for augmenting and/or restoring brain and nervous system function and inducing new neural connections using self-learning artificial networks |
US11617887B2 (en) | 2018-04-19 | 2023-04-04 | University of Washington and Seattle Children's Hospital Children's Research Institute | Systems and methods for brain stimulation for recovery from brain injury, such as stroke |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
JP7295141B2 (en) | 2018-04-27 | 2023-06-20 | ボストン サイエンティフィック ニューロモデュレイション コーポレイション | Multimodal electrical stimulation system and methods of making and using |
EP3784332B1 (en) | 2018-04-27 | 2023-04-26 | Boston Scientific Neuromodulation Corporation | Systems for visualizing and programming electrical stimulation |
CA3112564A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
US11766191B2 (en) * | 2019-06-28 | 2023-09-26 | Battelle Memorial Institute | Neurosleeve for closed loop EMG-FES based control of pathological tremors |
EP4304476A1 (en) * | 2021-03-10 | 2024-01-17 | Bruce E. Wexler | Pharmacotherapy of neurosystem dysfunctions |
Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3463328A (en) * | 1967-01-26 | 1969-08-26 | William T Blake | Draft gear train action control valve |
US3760984A (en) * | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3923426A (en) * | 1974-08-15 | 1975-12-02 | Alza Corp | Electroosmotic pump and fluid dispenser including same |
US3987790A (en) * | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
US3995631A (en) * | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US4016880A (en) * | 1976-03-04 | 1977-04-12 | Alza Corporation | Osmotically driven active agent dispenser |
US4036228A (en) * | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
US4203440A (en) * | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
US4203442A (en) * | 1977-08-29 | 1980-05-20 | Alza Corporation | Device for delivering drug to a fluid environment |
US4210139A (en) * | 1979-01-17 | 1980-07-01 | Alza Corporation | Osmotic device with compartment for governing concentration of agent dispensed from device |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4360019A (en) * | 1979-02-28 | 1982-11-23 | Andros Incorporated | Implantable infusion device |
US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
US4692147A (en) * | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US4725852A (en) * | 1985-05-09 | 1988-02-16 | Burlington Industries, Inc. | Random artificially perturbed liquid apparatus and method |
US6164284A (en) * | 1997-02-26 | 2000-12-26 | Schulman; Joseph H. | System of implantable devices for monitoring and/or affecting body parameters |
US6185452B1 (en) * | 1997-02-26 | 2001-02-06 | Joseph H. Schulman | Battery-powered patient implantable device |
US6208894B1 (en) * | 1997-02-26 | 2001-03-27 | Alfred E. Mann Foundation For Scientific Research And Advanced Bionics | System of implantable devices for monitoring and/or affecting body parameters |
US6227203B1 (en) * | 1998-02-12 | 2001-05-08 | Medtronic, Inc. | Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion |
US20010003799A1 (en) * | 1998-10-26 | 2001-06-14 | Boveja Birinder Bob | Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
US20020013612A1 (en) * | 2000-06-20 | 2002-01-31 | Whitehurst Todd K. | System and method for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion |
US6415184B1 (en) * | 1999-01-06 | 2002-07-02 | Ball Semiconductor, Inc. | Implantable neuro-stimulator with ball implant |
US6464387B1 (en) * | 2000-12-05 | 2002-10-15 | Fred Stogsdill | Magnetic stirrer having a channel for fluid |
US20020161403A1 (en) * | 2000-02-15 | 2002-10-31 | Meadows Paul M. | Deep brain stimulation system for the treatment of parkinson's disease or other disorders |
US20030036780A1 (en) * | 2001-07-28 | 2003-02-20 | Barrett Burke T. | Treatment of movement disorders by near-diaphragmatic nerve stimulation |
US6788975B1 (en) * | 2001-01-30 | 2004-09-07 | Advanced Bionics Corporation | Fully implantable miniature neurostimulator for stimulation as a therapy for epilepsy |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867164A (en) | 1983-09-14 | 1989-09-19 | Jacob Zabara | Neurocybernetic prosthesis |
US4702254A (en) | 1983-09-14 | 1987-10-27 | Jacob Zabara | Neurocybernetic prosthesis |
US5025807A (en) | 1983-09-14 | 1991-06-25 | Jacob Zabara | Neurocybernetic prosthesis |
US5312439A (en) | 1991-12-12 | 1994-05-17 | Loeb Gerald E | Implantable device having an electrolytic storage electrode |
US5193540A (en) | 1991-12-18 | 1993-03-16 | Alfred E. Mann Foundation For Scientific Research | Structure and method of manufacture of an implantable microstimulator |
US5193539A (en) | 1991-12-18 | 1993-03-16 | Alfred E. Mann Foundation For Scientific Research | Implantable microstimulator |
US6463328B1 (en) | 1996-02-02 | 2002-10-08 | Michael Sasha John | Adaptive brain stimulation method and system |
US6051017A (en) | 1996-02-20 | 2000-04-18 | Advanced Bionics Corporation | Implantable microstimulator and systems employing the same |
US5683422A (en) | 1996-04-25 | 1997-11-04 | Medtronic, Inc. | Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation |
US5716377A (en) | 1996-04-25 | 1998-02-10 | Medtronic, Inc. | Method of treating movement disorders by brain stimulation |
US5707396A (en) | 1996-04-25 | 1998-01-13 | Institute National De La Sante De La Recherche Medicale (Inserm) | Method of arresting degeneration of the substantia nigra by high frequency stimulation of subthalamic nucleus |
US6094598A (en) | 1996-04-25 | 2000-07-25 | Medtronics, Inc. | Method of treating movement disorders by brain stimulation and drug infusion |
US5711316A (en) | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
JP4157168B2 (en) | 1997-03-27 | 2008-09-24 | アルフレッド イー マン ファウンデーション フォア サイエンティフィック リサーチ | Implantable device system for monitoring and / or acting on body parameters |
US6016449A (en) * | 1997-10-27 | 2000-01-18 | Neuropace, Inc. | System for treatment of neurological disorders |
US6013449A (en) | 1997-11-26 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Probe-based analysis of heterozygous mutations using two-color labelling |
US6205359B1 (en) | 1998-10-26 | 2001-03-20 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
CO5111024A1 (en) | 1998-12-29 | 2001-12-26 | Kimberly Clark Co | COMPOSITIONS OF POLYMER COATINGS TRIPPED BY ION ON WATER SENSITIVE POLYMER FILMS |
US6464687B1 (en) | 1999-03-09 | 2002-10-15 | Ball Semiconductor, Inc. | Implantable drug delivery system |
US6356784B1 (en) | 1999-04-30 | 2002-03-12 | Medtronic, Inc. | Method of treating movement disorders by electrical stimulation and/or drug infusion of the pendunulopontine nucleus |
US20060241717A1 (en) * | 2001-08-30 | 2006-10-26 | Whitehurst Todd K | Treatment of movement disorders by extra dural motor cortex stimulation |
US7151961B1 (en) * | 2002-05-24 | 2006-12-19 | Advanced Bionics Corporation | Treatment of movement disorders by brain stimulation |
-
2003
- 2003-05-02 US US10/428,744 patent/US7151961B1/en not_active Expired - Fee Related
-
2006
- 2006-12-19 US US11/641,977 patent/US20070100393A1/en not_active Abandoned
-
2010
- 2010-08-31 US US12/873,170 patent/US8401634B2/en not_active Expired - Fee Related
Patent Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3463328A (en) * | 1967-01-26 | 1969-08-26 | William T Blake | Draft gear train action control valve |
US3995631A (en) * | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US3760984A (en) * | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3923426A (en) * | 1974-08-15 | 1975-12-02 | Alza Corp | Electroosmotic pump and fluid dispenser including same |
US4036228A (en) * | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US3987790A (en) * | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
US4016880B1 (en) * | 1976-03-04 | 1983-02-01 | ||
US4016880A (en) * | 1976-03-04 | 1977-04-12 | Alza Corporation | Osmotically driven active agent dispenser |
US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4203442A (en) * | 1977-08-29 | 1980-05-20 | Alza Corporation | Device for delivering drug to a fluid environment |
US4203440A (en) * | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
US4210139A (en) * | 1979-01-17 | 1980-07-01 | Alza Corporation | Osmotic device with compartment for governing concentration of agent dispensed from device |
US4360019A (en) * | 1979-02-28 | 1982-11-23 | Andros Incorporated | Implantable infusion device |
US4692147A (en) * | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
US4725852A (en) * | 1985-05-09 | 1988-02-16 | Burlington Industries, Inc. | Random artificially perturbed liquid apparatus and method |
US6164284A (en) * | 1997-02-26 | 2000-12-26 | Schulman; Joseph H. | System of implantable devices for monitoring and/or affecting body parameters |
US6185452B1 (en) * | 1997-02-26 | 2001-02-06 | Joseph H. Schulman | Battery-powered patient implantable device |
US6208894B1 (en) * | 1997-02-26 | 2001-03-27 | Alfred E. Mann Foundation For Scientific Research And Advanced Bionics | System of implantable devices for monitoring and/or affecting body parameters |
US6227203B1 (en) * | 1998-02-12 | 2001-05-08 | Medtronic, Inc. | Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion |
US20010003799A1 (en) * | 1998-10-26 | 2001-06-14 | Boveja Birinder Bob | Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
US6415184B1 (en) * | 1999-01-06 | 2002-07-02 | Ball Semiconductor, Inc. | Implantable neuro-stimulator with ball implant |
US20020161403A1 (en) * | 2000-02-15 | 2002-10-31 | Meadows Paul M. | Deep brain stimulation system for the treatment of parkinson's disease or other disorders |
US20020013612A1 (en) * | 2000-06-20 | 2002-01-31 | Whitehurst Todd K. | System and method for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion |
US6464387B1 (en) * | 2000-12-05 | 2002-10-15 | Fred Stogsdill | Magnetic stirrer having a channel for fluid |
US6788975B1 (en) * | 2001-01-30 | 2004-09-07 | Advanced Bionics Corporation | Fully implantable miniature neurostimulator for stimulation as a therapy for epilepsy |
US20030036780A1 (en) * | 2001-07-28 | 2003-02-20 | Barrett Burke T. | Treatment of movement disorders by near-diaphragmatic nerve stimulation |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7945619B1 (en) | 2004-09-20 | 2011-05-17 | Jitendra Chawla | Methods and apparatuses for reporting based on attention of a user during a collaboration session |
US20110196930A1 (en) * | 2004-09-20 | 2011-08-11 | Jitendra Chawla | Methods and apparatuses for reporting based on attention of a user during a collaboration session |
US20070005752A1 (en) * | 2005-06-29 | 2007-01-04 | Jitendra Chawla | Methods and apparatuses for monitoring attention of a user during a collaboration session |
US8504163B1 (en) * | 2006-06-30 | 2013-08-06 | Boston Scientific Neuromodulation Corporation | Cranially mounted stimulation systems and methods |
US20090054955A1 (en) * | 2007-08-20 | 2009-02-26 | Kopell Brian H | Systems and Methods for Treating Neurological Disorders by Light Stimulation |
US8788042B2 (en) | 2008-07-30 | 2014-07-22 | Ecole Polytechnique Federale De Lausanne (Epfl) | Apparatus and method for optimized stimulation of a neurological target |
US10952627B2 (en) | 2008-07-30 | 2021-03-23 | Ecole Polytechnique Federale De Lausanne | Apparatus and method for optimized stimulation of a neurological target |
US9072906B2 (en) | 2008-07-30 | 2015-07-07 | Ecole Polytechnique Federale De Lausanne | Apparatus and method for optimized stimulation of a neurological target |
US10166392B2 (en) | 2008-07-30 | 2019-01-01 | Ecole Polytechnique Federale De Lausanne | Apparatus and method for optimized stimulation of a neurological target |
US11759238B2 (en) | 2008-10-01 | 2023-09-19 | Sherwin Hua | Systems and methods for pedicle screw stabilization of spinal vertebrae |
US8788064B2 (en) | 2008-11-12 | 2014-07-22 | Ecole Polytechnique Federale De Lausanne | Microfabricated neurostimulation device |
US11123548B2 (en) | 2008-11-12 | 2021-09-21 | Ecole Polytechnique Federale De Lausanne | Microfabricated neurostimulation device |
US10406350B2 (en) | 2008-11-12 | 2019-09-10 | Ecole Polytechnique Federale De Lausanne | Microfabricated neurostimulation device |
US9440082B2 (en) | 2008-11-12 | 2016-09-13 | Ecole Polytechnique Federale De Lausanne | Microfabricated neurostimulation device |
US8774937B2 (en) | 2009-12-01 | 2014-07-08 | Ecole Polytechnique Federale De Lausanne | Microfabricated surface neurostimulation device and methods of making and using the same |
US9604055B2 (en) | 2009-12-01 | 2017-03-28 | Ecole Polytechnique Federale De Lausanne | Microfabricated surface neurostimulation device and methods of making and using the same |
US9192767B2 (en) | 2009-12-01 | 2015-11-24 | Ecole Polytechnique Federale De Lausanne | Microfabricated surface neurostimulation device and methods of making and using the same |
US10736533B2 (en) | 2009-12-21 | 2020-08-11 | Sherwin Hua | Insertion of medical devices through non-orthogonal and orthogonal trajectories within the cranium and methods of using |
US9642552B2 (en) | 2009-12-21 | 2017-05-09 | Sherwin Hua | Insertion of medical devices through non-orthogonal and orthogonal trajectories within the cranium and methods of using |
US9820668B2 (en) | 2009-12-21 | 2017-11-21 | Sherwin Hua | Insertion of medical devices through non-orthogonal and orthogonal trajectories within the cranium and methods of using |
US9179875B2 (en) | 2009-12-21 | 2015-11-10 | Sherwin Hua | Insertion of medical devices through non-orthogonal and orthogonal trajectories within the cranium and methods of using |
US9549708B2 (en) | 2010-04-01 | 2017-01-24 | Ecole Polytechnique Federale De Lausanne | Device for interacting with neurological tissue and methods of making and using the same |
US11766560B2 (en) | 2010-04-01 | 2023-09-26 | Ecole Polytechnique Federale De Lausanne | Device for interacting with neurological tissue and methods of making and using the same |
US10016600B2 (en) | 2013-05-30 | 2018-07-10 | Neurostim Solutions, Llc | Topical neurological stimulation |
US11229789B2 (en) | 2013-05-30 | 2022-01-25 | Neurostim Oab, Inc. | Neuro activator with controller |
US11291828B2 (en) | 2013-05-30 | 2022-04-05 | Neurostim Solutions LLC | Topical neurological stimulation |
US10307591B2 (en) | 2013-05-30 | 2019-06-04 | Neurostim Solutions, Llc | Topical neurological stimulation |
US10918853B2 (en) | 2013-05-30 | 2021-02-16 | Neurostim Solutions, Llc | Topical neurological stimulation |
US10946185B2 (en) | 2013-05-30 | 2021-03-16 | Neurostim Solutions, Llc | Topical neurological stimulation |
US11311718B2 (en) | 2014-05-16 | 2022-04-26 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
US10966620B2 (en) | 2014-05-16 | 2021-04-06 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
US10201707B2 (en) | 2014-08-27 | 2019-02-12 | Aleva Neurotherapeutics | Treatment of autoimmune diseases with deep brain stimulation |
US9925376B2 (en) | 2014-08-27 | 2018-03-27 | Aleva Neurotherapeutics | Treatment of autoimmune diseases with deep brain stimulation |
US10441779B2 (en) | 2014-08-27 | 2019-10-15 | Aleva Neurotherapeutics | Deep brain stimulation lead |
US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
US10065031B2 (en) | 2014-08-27 | 2018-09-04 | Aleva Neurotherapeutics | Deep brain stimulation lead |
US11730953B2 (en) | 2014-08-27 | 2023-08-22 | Aleva Neurotherapeutics | Deep brain stimulation lead |
US11167126B2 (en) | 2014-08-27 | 2021-11-09 | Aleva Neurotherapeutics | Deep brain stimulation lead |
US9403011B2 (en) | 2014-08-27 | 2016-08-02 | Aleva Neurotherapeutics | Leadless neurostimulator |
US9572985B2 (en) | 2014-08-27 | 2017-02-21 | Aleva Neurotherapeutics | Method of manufacturing a thin film leadless neurostimulator |
US9889304B2 (en) | 2014-08-27 | 2018-02-13 | Aleva Neurotherapeutics | Leadless neurostimulator |
US11077301B2 (en) | 2015-02-21 | 2021-08-03 | NeurostimOAB, Inc. | Topical nerve stimulator and sensor for bladder control |
US10953225B2 (en) | 2017-11-07 | 2021-03-23 | Neurostim Oab, Inc. | Non-invasive nerve activator with adaptive circuit |
US11266830B2 (en) | 2018-03-02 | 2022-03-08 | Aleva Neurotherapeutics | Neurostimulation device |
US11738192B2 (en) | 2018-03-02 | 2023-08-29 | Aleva Neurotherapeutics | Neurostimulation device |
US11160580B2 (en) | 2019-04-24 | 2021-11-02 | Spine23 Inc. | Systems and methods for pedicle screw stabilization of spinal vertebrae |
US11458311B2 (en) | 2019-06-26 | 2022-10-04 | Neurostim Technologies Llc | Non-invasive nerve activator patch with adaptive circuit |
US11730958B2 (en) | 2019-12-16 | 2023-08-22 | Neurostim Solutions, Llc | Non-invasive nerve activator with boosted charge delivery |
Also Published As
Publication number | Publication date |
---|---|
US20100331807A1 (en) | 2010-12-30 |
US7151961B1 (en) | 2006-12-19 |
US8401634B2 (en) | 2013-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8401634B2 (en) | Treatment of movement disorders by brain stimulation | |
US7155279B2 (en) | Treatment of movement disorders with drug therapy | |
US8467879B1 (en) | Treatment of pain by brain stimulation | |
US7003352B1 (en) | Treatment of epilepsy by brain stimulation | |
US8718779B2 (en) | Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion | |
US20060241717A1 (en) | Treatment of movement disorders by extra dural motor cortex stimulation | |
US6782292B2 (en) | System and method for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion | |
US6950707B2 (en) | Systems and methods for treatment of obesity and eating disorders by electrical brain stimulation and/or drug infusion | |
US7493171B1 (en) | Treatment of pathologic craving and aversion syndromes and eating disorders by electrical brain stimulation and/or drug infusion | |
US7684867B2 (en) | Treatment of aphasia by electrical stimulation and/or drug infusion | |
US6862479B1 (en) | Spinal cord stimulation as a therapy for sexual dysfunction | |
US20040225335A1 (en) | Treatment of Huntington's disease by brain stimulation | |
US7769461B2 (en) | Skull-mounted electrical stimulation system and method for treating patients | |
US6922590B1 (en) | Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion | |
US7440806B1 (en) | Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion | |
US8630705B2 (en) | Implantable stimulator | |
US7890176B2 (en) | Methods and systems for treating chronic pelvic pain | |
US8515541B1 (en) | Methods and systems for treating post-stroke disorders | |
US20050182453A1 (en) | Treatment of epilepsy by high frequency electrical stimulation and/or drug stimulation | |
US20070038264A1 (en) | Methods and systems for treating autism | |
US20060178709A1 (en) | Methods and systems for treating a medical condition by promoting neural remodeling within the brain | |
US9352145B2 (en) | Methods and systems for treating a psychotic disorder | |
US9095713B2 (en) | Methods and systems for treating autism by decreasing neural activity within the brain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BOSTON SCIENTIFIC NEUROMODULATION CORPORATION, CAL Free format text: CHANGE OF NAME;ASSIGNOR:ADVANCED BIONICS CORPORATION;REEL/FRAME:020405/0722 Effective date: 20071116 Owner name: BOSTON SCIENTIFIC NEUROMODULATION CORPORATION,CALI Free format text: CHANGE OF NAME;ASSIGNOR:ADVANCED BIONICS CORPORATION;REEL/FRAME:020405/0722 Effective date: 20071116 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |